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ABSTRACT
Introduction: Despite a lower incidence of breast cancer (BrCA) among Black women
in the U.S. compared to White women, Black women experience consistently higher
mortality rates. The aims of this study were 1) to assess the relationship between race and
diagnosis-to-treatment times 2) to assess racial disparity in mortality among Black and
White BrCA patients in SC and 3) assessment of the validity of the Mortality-toincidence ration (MIR) as a proxy for survival and geospatial investigation of racial
disparity among breast cancer (BrCA) patients.
Methods: Breast cancer cases diagnosed between 2002-2010 were obtained
retrospectively from the SC Central Cancer Registry, linked with administrative data
from a private payor source and Medicaid Plan. The main exposure variable for all
analyses was patient’s race (White vs Black women). For aim 1, outcome variables were
diagnosis-to-treatment time for BrCA-related surgery, radiation, adjuvant hormone
treatment (AHT) and chemotherapy; Chi-square tests, logistic regression and generalized
linear model analyses were conducted to compare patients’ diagnosis-to-treatment times
among Blacks and Whites. For aim 2, the main outcome variable was mortality
characterized by vital status and total survival time; Cox proportional hazard analyses
were conducted to compare hazard ratios among Blacks and Whites to assess disparities
in mortality. For aim 3, MIRs were computed from cancer incidence and mortality data
which were obtained from the SC Community Access Network (SCAN). ArcGIS 10.2
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was utilized to map BrCA MIRs by race (46 counties and 4 regions). MIR were
categorized into seven levels using the national BrCA MIR for White women as
reference in county maps; in all other maps, categorizations were based on natural breaks
in ArcGIS. Survival percentage, Cox Proportional hazard ratios and survival-MIR
correlation analyses were computed for all BrCA cases in each county/region utilizing
SAS software and data on BrCA cases which were obtained retrospectively from the SC
Central Cancer Registry from 2002 to 2010.
Results: A total of 2155 BrCA patients with 1557 White women and 598 Black women
were reported in the study period (2002-2010). For aim 1, multivariable linear model
regression showed that there was statistically significant increase in adjusted least square
means in receipt of AHT by 54 days, 36 days, 63 days and 46 days among unmarried, not
being on best chance network and late surgery; multivariable logistic regression showed
that the odds of late receipt of surgery was 1.96 (95% CI: 1.38-2.79) among unmarried
Black women compared with unmarried White women; 1.89 (95% CI: 1.32-2.71) among
Black women who lived <=10 miles to their health providers compared to White women
who lived <=10 miles; and 1.40 (95% CI: 1.08-1.82) among Black women who live in
urban areas compared with White women who lived in urban areas. For aim 2,
multivariable Cox proportional hazard that adjusted for cancer stage showed that the
hazard ratio of mortality was 3.45 (1.64, 7.25) among Black women who lived in Low
Country region of the state compared with White women who lived in Low Country
region of the state. There were no statistically significant differences between White and
Black women in the other 3 regions of the state (Midlands, PeeDee and Upstate). For aim
3, there were multiple statistically significant correlations between MIR and survival
v

overall; MIR and survival among Whites; and Black-White difference in MIR versus
Black-White difference in survival (all p-values were <0.05). Low Country region was
identified as the region with worse Black-White MIR and survival disparity.
Conclusions: Mortality was higher among Blacks who lived in the Low Country region
of the state and among Blacks who lived in urban areas. Health region ranking utilizing
the MIR correlated with 12-year survival time in the overall population, Whites and
Black-White difference. To improve overall timely receipt of AHT, efforts need to be
directed at Black BrCA patients that are not married, not on BCN, and those that received
late surgery. To improve overall timely receipt of surgery, efforts need to be directed at
Black BrCA patients that are not married, lived in urban areas and lived <=10 miles from
their health providers.
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CHAPTER 1

INTRODUCTION
Statement of the Problem
Statistics over the past 20 years in the United States have shown higher mortality
rates among Blacks with breast cancer (BrCa) compared to Whites despite lower
incidence of BrCa among Blacks. (1-4) In South Carolina (SC), there is a 60% higher risk
of Black women dying from BrCa compared to White women (5), with an even higher
risk of BrCa mortality among those with a low socioeconomic status. (6, 7) A delay in the
commencement of treatment has been hypothesized as one of the possible reasons for the
higher mortality among Blacks despite lower incidence over the years. (3) Survival
studies have shown that a treatment delay of as little as two months is associated with less
favorable survival among BrCa cases. (3, 8, 9)
The mortality-to-incidence ratio (MIR) is a unique way to quantify cancer
disparities based on race (5, 10). The MIR is an important indicator that offers additional
information beyond what is represented through the individual incidence and mortality
rate measures (5), however, few studies have used MIRs to compare cancer rates (5, 1113). Wagner et al. described racial cancer disparities and their potential geographical
determinants by calculating, comparing and mapping MIRs throughout the state of
Georgia (GA, United States). This study found that Blacks in GA had more fatal cancers
1

than Whites for all cancer sites evaluated (10). Furthermore, Sunkara et al. demonstrated
a strong linear relationship between the MIR for colorectal cancer and health system
rankings across the countries evaluated (14). While there are many advantages to using
the MIR as surveillance tool, MIR lacks the ability to capture loss to follow up and
censoring. However, survival analyses can capture and account for follow up. Due to this
difference between MIR and survival analyses, there is need to conduct sensitivity
analyses to compare rankings between MIRs and median survival times across regions in
SC by race. This will serve to validate the MIR.
Background
The time from diagnosis to the first course of treatment among cancer patients,
including BrCa patients, increased from 1995 to 2005. (15) From 1995 to 2005, there was
an increase in average wait time to BrCa surgery from 21 days to 32 days, clearly
revealing an increase of 11 days over the years. (16) Diagnosis-to-surgery wait times
among BrCa patients in the United States have also increased over the past 20 years. (15,
17, 18) In terms of surgical interventions for BrCa patients, disparities exist between
races in wait times from diagnosis to surgery, with significantly higher odds of delayed
treatment among Blacks and Hispanics. (18)
The various forms of delay that Black women diagnosed with BrCa experience
are related to diagnosis, (19) as well as time to surgery, (3, 20, 21) chemotherapy, (4, 22,
23) adjuvant hormonal therapy,(24-26) and all forms of treatment combined. (27, 28)
Documented factors that affect delay in treatment among BrCa by race include age, (28)
hospital type, (23) trust in oncologists and communication with physicians. (4) Delays in
2

adjuvant therapy among BrCa patients have been shown to worsen survival (18, 29) and
increase patient anxiety. (18)
Previous studies have utilized the MIR as a surveillance tool and shown that SC
exhibits more extreme racial differences in cancer incidence, mortality and MIR than
other states or the nation. (30-38) Additionally, examining the MIR helped to highlight
health regions where this disparity is highest. (38) The MIR also serves as a populationbased approximation of fatality (1/survival) given incidence by stabilizing the incidence
and mortality differences across cancer sites and racial groups (5, 10). The MIR is also a
unique way to quantify racial cancer disparities (5, 10). Few studies have used the MIR to
compare cancer rates (5, 11-13). Wagner et al. described racial cancer disparities and
their potential geographical determinants by calculating, comparing and mapping MIRs
throughout the state of Georgia (GA, United States) and found that Blacks in GA had
higher rates of fatal cancers than Whites for all cancer sites evaluated (10, 14). Strong
recommendations have been made for cancer surveillance programs to use MIRs to
monitor disparities across racial/ethnic groups and geographic regions (5, 10-14, 38) as a
proxy for survival, but there has not yet been a study to assess the effectiveness of MIR
as a proxy for survival among BrCa patients, especially in South Carolina where there is
marked Black-White disparity. (38)
Proposal and Specific Aims
Effective reduction of disparities in treatment delays and mortality among racial
minorities will require the identification of the mechanisms by which these disparities
occur. I propose to assess racial disparities in BrCa treatment and mortality in SC by
3

utilizing data derived from all female BrCa cases over eight years from the SC Central
Cancer Registry linked with administrative medical and pharmacy claims data for the
Public Employee Benefits Plan (private, state-subsidized insurance plan for state
employees) and Medicaid.
This combination of data from both publicly and privately insured BrCa patients
will be utilized to assess the complex interplay between geographic factors and racial
disparities using Geographical Information System (GIS) mapping, survival methods and
multilevel models to identify predictors of treatment delays and mortality that can be
intervened upon. GIS methods have been utilized to identify possible predictors of racial
disparities in breast cancer survival. (39) However, GIS methodology has not been
utilized to specifically identify individual- and area-level characteristics that may
contribute to BrCa mortality among Blacks within the context of multilevel survival
modeling. Recognition of the causes of disparities in small-area variation in BrCa
survival has the potential to allow the application of evidence-based approaches to reduce
disparities. (39)
The aims of this study therefore are to 1) assess racial disparities in treatment
delays and the utilization of adjuvant hormonal therapy (AHT) among patients diagnosed
with breast cancer and 2) identify predictors of dissimilarity in breast cancer-related
survival by health regions among Black women in SC utilizing multilevel survival
models and GIS methodologies. The above-mentioned dataset will also be used for
survival analyses to compute the median survival time for the four health regions in SC in
order to rank the health regions. Thereafter, the survival and the ranking derived from the
MIRs will be compared.
4

The Specific Aims
1. To assess racial disparities in breast cancer treatment time in South Carolina (SC).
a. To compare wait times from diagnosis to the various forms of treatment in
Blacks and Whites with BrCa.
b. To assess the effect modifiers (diagnosis year and rural/urban status) that
affect the relationship between race (Black vs White) and diagnosis-totreatment wait times for the different treatment types.
Hypothesis: We hypothesize that the diagnosis-to-treatment wait time is higher among
Blacks compared to Whites for all BrCa treatment types in SC. We also hypothesize that
diagnosis year and rural/urban status will be an effect modifier in the relationship
between race and diagnosis-to-treatment wait times. Assessing for effect modifications
between race and important modifiers will also help identify specific modifier groups that
help explain the racial disparity among Blacks, which will aid in the development of
multilevel interventions.
2. To identify patient- and neighborhood-level predictors of dissimilarity in breast
cancer-related survival among Blacks and Whites in SC utilizing multilevel (state and
regional) survival models.
a. To analyze the breast cancer-specific and overall survival in SC as a whole, as
well as by four health regions, utilizing the Kaplan-Meier curve and median
survival time.
b. To identify predictors of survival by four health regions utilizing the Cox
proportional hazard ratios.
5

Hypothesis: We hypothesize that treatment and mortality outcomes will be worse in
Regions 6 and 4, which are characterized by lower socioeconomic status, and will be
better in Regions 2 and 7 because of the major hospital systems available in these
regions.
3. To compare MIR methodology with survival methodology in assessing racial BrCa
disparities over the eight-year period across the four health regions in SC.
a. Describe BrCa disparities in SC among Blacks and Whites using MIRs by
race for the four health regions within SC.
b. Rank the four health regions by race from the worst to the best using MIRs.
c. Compute the median survival time by race in the four health regions.
d. Rank the four health regions by race from the worst to the best using median
survival times.
e. Compare the rankings based on MIRs to those from median survival times to
see where differences exist.
Hypothesis: We hypothesize that the findings from MIR by regions will be similar to the
survival analyses by regions.

Significance of this study
Although various studies in other states consistently show that Black women with
BrCa experience delays in receipt of surgery, chemotherapy, AHT and radiation, (3, 4,
19-23, 27, 28) this has not been examined in SC, which has a high representation of
minority and rural populations. SC has well-documented inter-racial differences in cancer
6

incidence and mortality (30-38). In addition, the possible factors that affect racial
disparity in treatment delays in SC have not been examined.
The need to study predictors of disparities in diagnosis-to-treatment times and
their effects on survival among BrCa patients in SC is particularly important because
Black-White disparity in BrCa mortality is of a higher magnitude in SC (30, 40, 41);
mortality among White BrCa patients is 7% lower in SC compared to the national
average and is 29% higher among Blacks in SC (30, 40, 41). Also, in SC, mortality from
BrCa amongst Blacks is greater than 60% higher than that of Whites (5). Studies also
show that Blacks experience worse mortality outcomes after matching for known
prognostic factors, and this finding has persisted over time (42-45).
A study that used three cutoff points (30, 60, 90 days) to define a diagnosis-tosurgery delay showed that Black women were more likely to experience delays compared
to White women, and this association was independent of health insurance status, age at
diagnosis and cancer stage at diagnosis (46). There is therefore a need to assess other
factors that influence delay to surgery apart from health insurance, age at diagnosis and
cancer stage at diagnosis and to examine how these factors interplay with survival
outcomes (21). This study was able to assess other factors such as marital status, county
of residence (whether rural or urban), year of diagnosis, hormone receptor status,
enrolment in BCN (dichotomized as yes or no), and tumor grade of BrCa at diagnosis.
This study also helped to assess the extent to which radiation treatment guidelines
are being adhered to among BrCa patients in SC. For example, the national guideline
consensus by the National Institutes of Health (NIH) and American Society of Clinical
7

Oncology (ASCO) states that BrCa patients who have high risk for locoregional
recurrence should receive postmastectomy radiation (PMRT) (47-52). This study helped
to assess if PMRT is being adhered to and if racial disparities exists in SC. Additionally,
the effect of diagnosis-to-radiation time and surgery-to-radiation time on survival by race
in SC added to current body of knowledge (53) in overall survival and BrCa specific
survival. This study also helped to assess the extent to which chemotherapy treatment
guidelines are being adhered to among BrCa patients in SC. For example, the
recommendation from clinical trials is that adjuvant chemotherapy be initiated within 3
months after surgical intervention (54).
Because of the excess contribution of hormone receptor negative (HRN) BrCa
patients to mortality among BrCa patients, it is important to study and identify factors
that are associated with the receipt of recommended treatment guidelines, inclusive of the
recommended 60 days between diagnosis and treatment for BrCa among HRN BrCa
patients (55). This information will help guide interventions that will help reduce
disparities among Black women (55).
The association between race and commencement of AHT is not well elucidated
and appears to be incompletely studied and controversial; thus, further work is required.
In North Carolina (NC), statistically significant racial disparity in commencement of
AHT has been demonstrated: Blacks were less likely to commence AHT, and this racial
disparity was more pronounced among the subpopulation of patients that did not receive
chemotherapy. (26) However, in a previous study in SC, there was no racial difference
found between Blacks and Whites in the commencement and early use of AHT, but
further analysis showed that receipt of chemotherapy/radiation was independently
8

associated with commencement/early use of AHT. (6) In SC, contrary to the finding in
NC, overall use of AHT was worse among patients who received AHT and/or radiation.
(6) In the study described above in NC, the BrCa cases were privately insured (26);
however, in the study in SC (6), the BrCa cases were on Medicaid insurance. Perhaps the
difference in the insurance payer of the BrCa cases between the two studies could help
explain the differences in the results. To further understand the interplay between race,
commencement of AHT and other forms of treatments for BrCa, there is a need to
analyze data on all BrCa cases derived from the Central Cancer Registry linked with
administrative medical and pharmacy claims data for the Public Employee Benefits Plan
(private insurance) and Medicaid. This study will be able to achieve this.
This study also added to existing body of literature on racial disparities BrCaspecific survival (BSS), (56) and overall survival (OS) (57, 58). Assessment of predictors
of survival differences in this study by regions in SC has not been studied before
therefore findings from this research will help navigation programs to identify regions
with higher racial disparities and also help to identify possible modifiable predictors that
are driving the disparities.
The epidemiologic use of the MIR in cancer research is gaining significance and
is increasingly used. (5, 10-14, 38) A major drawback of the MIR, however, is that there
is no method to account for censoring and loss to follow up. Additionally, the MIR most
likely counts the mortality from previous years while using incidence from the current
year hence it is not a classic case fatality proportion. It is also not possible to adjust for
covariates such as treatment, comorbidities or individual socioeconomic status in MIR
analysis. Another weakness is that the relationship between the numerator (mortality) and
9

the denominator (incidence) may not be direct because persons diagnosed with BrCa may
not die of BrCa, and persons who die after the diagnosis of BrCa will survive for varying
lengths of time, which the MIR cannot account for.
The limitations of the MIR described above make it difficult to compare results of
MIR studies directly with those of survival studies. Survival studies are more complex,
time-consuming and expensive and require more skills to carry out. Using MIR is less
time-consuming, less expensive and requires fewer skills to carry out. (5) The potential
utility of the MIR in cancer surveillance programs for monitoring disparities across
racial/ethnic groups and geographic regions is substantial, as shown by previous studies.
(5, 10, 12, 14, 38) It is therefore important to see how the MIR compares with survival
studies in identifying racial disparities and in ranking health regions for the purpose of
surveillance.
This study found that the health region rankings are similar whether using MIR or
survival time, hence it may be preferable to use the cheaper, faster and less timeconsuming MIR, which also requires fewer skills, to identify racial disparities and rank
health regions to identify areas that require urgent attention/interventions. To our
knowledge, this is the first study that sought to directly compute MIR by health regions
and compare this ranking with a ranking produced by median survival time to further
substantiate the usefulness of the MIR in resource-poor settings and in quick decision
making to identify areas that need urgent interventions.
Additionally, a previous report shows that predictors that are environmental in
nature affect health and disparity, (59) but the influence of geographical factors has not
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been well explored among younger women. This is particularly important because young
Black women (less than 65 years old) present with relatively more fatal BrCa, leading to
higher mortality among this group. (30, 40) This proposed project aims to focus on this
relationship among the target population.
Overall, the study population (SC) being considered in this study is unique
because of the high proportion of SC residents that live in rural areas and the high racial
disparity found in SC in other studies. The proposed analytic techniques in this study are
also unique because the MIR has not been utilized to assess BrCa disparities in SC and
this will be the first study conducting a direct sensitivity analyses comparing MIR with
survival analyses both on the state-wide level and regional level. Identifying predictors of
racial differences in survival by regions is also unique as findings has the potential to
help guide more result-oriented navigation efforts.
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CHAPTER 2

LITERATURE REVIEW
Disproportionate Breast Cancer Burden among Blacks
Despite the awareness and funding dedicated to closing the racial gap in cancer
therapy, it is discouraging to note that racial disparities persist in BrCa mortality (60, 61).
Compared with non-Hispanic Whites, Blacks bear an excessive public health burden of
BrCa in the United States (1, 2, 62). Mortality due to BrCa is encountered at a much
higher rate among Blacks compared to Whites (40, 63, 64). Mortality from BrCa is about
40% higher among Blacks compared to Whites, although Whites have a higher likelihood
of being diagnosed with BrCa (6, 65, 66). The lifetime probability of developing BrCa is
1 in 9 among non-Hispanic Whites and 1 in 8 among Blacks. However, the lifetime
probability of dying from BrCa is 1 in 37 among non-Hispanic Whites but 1 in 31 among
Blacks (2). The mortality rate from BrCa is 22 per 100,000 among non-Hispanic Whites
and 31 per 100,000 among Blacks (2).
Although the Black-White disparity in BrCa mortality is seen both at the national
level and in SC specifically, the disparity is of a higher magnitude in SC (30, 40, 41);
mortality among White BrCa patients is 7% lower in SC compared to the national
average and is 29% higher among Blacks in SC (30, 40, 41). Also, in SC, mortality from
BrCa amongst Blacks is greater than 60% higher than that of Whites (5). Studies also
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show that Blacks experience worse mortality outcomes after matching for known
prognostic factors, and this finding has persisted over time (42-45).
Results from meta-analyses of BrCa that were conducted in 2002 and 2006
showed that there was about 20% excess risk of death among Blacks compared to Whites
(67, 68). The pooled hazard ratio of mortality among Blacks compared with Whites was
1.22 (95% C.I.: 1.13-1.30) in 2002 and 1.28 (95% C.I.: 1.18-1.38) in 2006 (67, 68). The
meta-analysis revealed that there were clear survival disadvantages among Blacks with
BrCa in all studies considered (67, 68).
Factors that Contribute to Higher Mortality among Black BrCa Cases Compared to
Whites
Identified factors that contribute to a higher mortality among Blacks compared to
Whites in the US are socioeconomic status, tumor biology (more aggressive tumors),
disability, environmental factors, comorbidities, cultural differences, late stage at
diagnosis and age at diagnosis (21, 22, 41, 69-77). Severe obesity and high waist-to-hip
ratio among Blacks have also been found to contribute to racial differences in stage at
BrCa diagnosis, as Blacks had a higher likelihood of severe obesity and being in the
highest tertile of waist-to-hip ratio (64).
Blacks also have various barriers to accessing care and have been shown to
consistently receive lower-than-recommended BrCa care when compared with their
White counterparts (21, 25, 43, 61, 73, 78). This includes lower-than-recommended rates
of radiation after surgical treatment for BrCa (25, 43, 61, 78). Blacks have also been
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shown to be 30-40% more likely to receive BrCa treatments that are not in line with
guidelines across all BrCa subtypes (79).
Socioeconomic status (SES) has been identified as one of the main drivers of
racial disparities in BrCa mortality, as women in low socioeconomic levels tend to
present with more advanced-stage BrCa, which usually has poorer prognosis (71, 80).
Generally, the five-year survival rate is worse among population subgroups with lower
SES, which are usually comprised of a large proportion of Blacks (71, 81). Whereas
about 12% of Whites live below the poverty level, this proportion is 26% among Blacks
(71, 82).
Previous studies have also shown that there is a tendency among Blacks to not
receive preventative services such as early screening mammograms (77). Blacks are also
likely to have BrCa with low pathologic complete response (pCR) to chemotherapy (56).
pCR has been shown to be a major prognostic index, as higher pCR has been linked with
better survival outcomes (56). Blacks have also been shown to have a larger median
tumor diameter at presentation and also to present with triple-negative BrCa (TNBC)
(83).
Treatment Guidelines for Breast Cancer
The national guideline consensus by the National Institutes of Health (NIH) and
American Society of Clinical Oncology (ASCO) states that BrCa patients who have high
risk for loco-regional recurrence should receive post-mastectomy radiation (PMRT) (4752). For stages I and II BrCa, there are two recommended forms of treatment:
lumpectomy i.e., breast conserving surgery (BCS), followed by whole-breast radiation
14

therapy; and a modified form of a radical mastectomy with or without radiation therapy
(78, 84, 85). PMRT is indicated only when the tumor size is large and three or more
lymph nodes are affected (43, 84-86). A study that assessed the recurrence of BrCa
comparing women with lumpectomy without radiation therapy and women with
lumpectomy with radiation therapy showed recurrence rates of 14% and 39%,
respectively, among the two groups (53).
Both forms of treatments for stage I and II BrCa have been shown to lead to
similar outcomes (53) in overall survival, disease-free survival and distant disease-free
survival. An additional recommendation for women with hormone receptor–positive
(HRP) BrCa is that those women with progesterone-positive (PR) or estrogen-positive
(ER) BrCa receive AHT for five years post diagnosis. (43, 85). This recommendation is
particularly useful for all BrCa that is 1 cm or greater in size. Irrespective of the stage or
size of the BrCa, the guideline recommends that ER or PR status should be determined
(43, 85).
A predefined cutoff of 60 days was set by the National Breast Cervical Cancer
Early Detection Program (NBCCEDP) between an abnormal screening test and diagnosis
and between diagnosis and initiation of treatment (21, 60, 74). The cutoff set by
NBCCEDP is that BrCa patients who experience delays of more than 60 days in initiation
of treatment should not comprise more than 20% of all BrCa patients (21, 60, 74). The
NBCCEDP has seen some success in the initiation of treatment for BrCa as a result of
this benchmark (8, 60, 87).
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Definition and Importance of Treatment Delays among BrCa Patients
The treatment interval was defined as the time in days between diagnosis of BrCa
and initiation of treatment, as in Caplan et al., Connors et al. and McLaughlin (8, 74, 88).
The date of diagnosis was defined as biopsy date, which was utilized as a proxy for
biopsy-confirmed BrCa diagnosis (8, 74, 88). The date of initiation of treatment was
defined as the date of definitive surgery, the date of initiation of neoadjuvant
chemotherapy or the date of initiation of AHT (8, 74, 88). For surgical treatment,
definitive surgery was determined as the most invasive surgery of the primary BrCa site
(74, 89). Examples of definitive surgeries include mastectomy, lumpectomy, excisional
biopsies and re-excision of the site of biopsy (74, 89).
Other authors have referred to the treatment interval by other names, such as
treatment delay or delay interval (90, 91). Past categorizations of treatment intervals have
used 4 groups, i.e., <30, 31-59, 60-69 and >90 days (74, 89). Another author used the
term time to primary treatment (TPT) to describe period between the date of pathological
diagnosis and the date of primary treatment (92). BrCa patients have also been defined as
having a treatment delay if they had a treatment interval greater than 60 days (74, 89).
As mentioned above, those patients who experience delays greater than 60 days should
not comprise more than 20% of the total patients, according to NBCCEDP (21, 60, 74).
However, studies show that delays greater than 90 days have the potential to lead to
worse BrCa outcomes, especially poorer survival (8, 54, 74, 93).
The diagnosis-to-treatment interval is an important quality measure that is
recognized by the National Accreditation Program for Breast Centers (NAPBC), the
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American Society of Breast Surgeons (ASBS) and the National Quality Measures for
Breast Care (NQMBC) (94-96). The NAPBC, ASBC and NQMBC all serve to validate
breast cancer care rendered by hospitals (94-96). However, there has been no formal
agreement on what constitutes an acceptable delay in terms of quality of BrCa care
measures (94-96). Another reason that the diagnosis-to-treatment wait time is important
is that studies have shown one of the most overwhelming, distressing and anxietyproducing periods for BrCa patients is the waiting time between an abnormal
mammogram and treatment initiation (94, 97).
Racial Disparities in the Receipt/Delay in the Receipt of Recommended Treatments
Generally, disparity in the utilization of various treatment forms such as surgery,
radiotherapy, chemotherapy and AHT has been hypothesized as the cause of the
disproportionate increase in mortality from BrCa (21, 77, 98). There is a higher
likelihood that a Black woman will experience treatment delay and/or discontinuation of
treatment for BrCa when compared with a White woman (46, 90, 99). Fedewa et al.
found that irrespective of stage of BrCa at diagnosis, age and the health insurance status
of the BrCa patient, Blacks had a higher likelihood of delay in receipt of treatment for
BrCa (46). Another study also showed that the odds of a Black BrCa patient experiencing
diagnosis-to-treatment delay beyond 1 month were 1.6 times (95% C.I.: 1.4-1.9) those of
White women (90).
A study in Missouri showed that the median diagnosis-to-treatment wait time for
any first course of treatment among Blacks was 27 days and that about 12% of Black
women had treatment delays above 60 days (74). In North Carolina, the median
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diagnosis-to-treatment wait time was 22 days (8). Similar results were also seen
internationally, as a study in Malaysia found that the median TPT was 18 days, and most
of the BrCa patients’ primary treatment was surgery (92).
Surgery
To define a delay, a predefined cutoff of 60 days was set by the NBCCEDP
between abnormal screening test and diagnosis and also between diagnosis and initiation
of treatment, which is surgery in most BrCa cases (21, 60). Compared with White
women, a large proportion of Blacks do not undergo surgical intervention for invasive
BrCa (72). There has also been an increase over time in the diagnosis-to-surgery wait
time among Medicare patients from 29 days (1992) to 32 days (2006) (16). In addition,
another study showed that time to surgery increased over time from a mean of 22 days
(1998) to 31 days (2003) to 41 days (2008) (100). A study assessing the effect of race on
diagnosis-to-treatment time showed that about 15% of Blacks experienced treatment
delay (>6 weeks) compared to about 8% of White women (9). Sheppard et al. showed
that the mean diagnosis-to-treatment time for Blacks and Whites were 47 days and 33
days, respectively, and that Black women were 58% less likely to have surgery within 90
days (21).
A study that used three cutoff points (30, 60, 90 days) to define a diagnosis-tosurgery delay showed that Black women were more likely to experience delays compared
to White women, and this association was independent of health insurance status, age at
diagnosis and cancer stage at diagnosis (46). Another study that utilized a cutoff point of
60 days showed that the odds of Black women experiencing a delay were 3.0 (C.I.: 1.918

5.0) compared to White women (98). There is therefore a need to assess other factors that
influence delay to surgery apart from health insurance, age at diagnosis and cancer stage
at diagnosis and to examine how these factors interplay with survival outcomes (21).
Some of the factors that were identified as delaying the interval from diagnosis to surgery
were ordering an MRI, systemic imaging, the type of surgery to be performed, patient
choice and plastic surgery consultation (17). In terms of type of surgery, a study found
that the mean time from consultation to lumpectomy was 22 (+16) days, the mean time to
mastectomy was 37 (+29) days, and the mean time to mastectomy with reconstruction
was 38 (+16) days (101). Other factors that were identified as influencing late receipt of
surgery among Blacks were mode of detection, health insurance and tumor size (98).
Radiotherapy
Radiotherapy is recommended for stage I and II BrCa patients following BCS;
however, Black women and other racial/ethnic minorities usually do not receive
radiotherapy (25, 78, 91). Local recurrence of BrCa has been shown to be higher among
patients that had BCS without concomitant radiotherapy (72, 102). Studies have shown
that there were disparities in the receipt of radiotherapy by racial/ethnic minorities, as the
odds of Black women experiencing radiation delay were 1.92 (95% C.I.: 1.55-2.37)
compared to White women (78, 103). Black women with BrCa had a higher likelihood of
receiving delayed radiotherapy after surgery compared to White women (98). Delay in
receipt of radiation was defined as receiving radiotherapy at least 8 weeks after surgery
(103).
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Freedman et al. hypothesized some possible reasons for the racial disparities,
including distance to treatment sites, inability to get time off work, childcare and limited
transportation (78). Another possible reason that racial/ethnic minorities may not receive
radiation therapy is that doctors may feel that the risks outweigh the benefits in older
patients. However, after excluding older women (>69 years old) from their study,
Freedman et al. still saw striking disparities affecting racial/ethnic minority groups,
suggesting that there are other reasons for the disparities besides age (78).
Adjuvant Hormone Therapy (AHT)
Adjuvant hormonal therapy (AHT) has been shown to improve both short- and
long-term survival among HRP BrCa patients worldwide, as it reduces BrCa mortality
and reoccurrence by 33% and 40%, respectively. (104) Annually, over 100,000 women
diagnosed with BrCa are classified as HRP, which has the potential of being cured (69,
105) if BrCa patients commence and adhere to treatment with AHT. United States
National Guidelines for the use of AHT recommends that women with HRP BrCa receive
AHT for 5 years (85, 106, 107). AHT is a prescription oral medication, and studies show
that current rates of adherence are between 50% and 75%, and most BrCa patients
discontinue the medication within the first year after prescription (108-112).
The advantages of AHT notwithstanding, 10-30% of eligible BrCa patients never
start treatment with AHT, (113, 114) and many who start AHT never adhere to or
complete the treatment, (111, 112, 115) leading to recurrence and increased mortality.
(116) Specifically, a study in New Zealand showed that suboptimal usage of AHT led to
increased BrCa mortality and recurrence among a specific ethnic group in New Zealand
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compared to Whites. (117) However, the association between race and commencement of
AHT is not well elucidated and appears incompletely studied and controversial; thus,
further study is warranted.(6, 26)
Assessment of AHT use
There are various ways to assess use of AHT among BrCa patients. One method
is to assess if a BrCa patient ever used AHT (6). Patients referred to as ever-users are
those who have at least one pharmacy claim record for any AHT medication during the
study period (6). Determination of ever use of AHT can be done by utilizing records in
the registry data or the pharmacy claims data, including claims for tamoxifen or
aromatase inhibitors such as exemestane, letrozole and anastrozole (6, 69, 118-123).
Another way to assess the use of AHT is to determine early/late initiation of AHT
after a diagnosis is made (6). In this case, patients who received AHT within 12 months
of diagnosis are categorized as early users, and those that started treatment with AHT
after 12 months will be categorized as late users (6).
A third mechanism to determine use of AHT is the medication possession ratio
(MPR) (6, 69, 112, 114, 115, 124). MPR here is defined as the AHT prescription supply
per unit time (days) for the year following the start of AHT (or until data is censored by
disenrollment). In order to calculate the MPR, the numerator is the total days covered by
the medication (using total day supply) and the denominator is the number of days for
which the supply is needed (69, 112, 114-116, 121-123). A ratio of more than 80% is
usually classified as adherence to treatment (114, 125).
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Another method to assess AHT use is adherence, which is further divided into
duration of treatment, persistence and consistent daily use of AHT (126). Adherence to
prescribed AHT is the degree to which a patient’s behavior in taking AHT corresponds
with the medical recommendation (126). Persistence is the time period for which a
patient continues to fill prescriptions after the initial filling, and the interval between
prescription refills is usually measured and reported (114, 125-127). Prescription rate has
also been utilized to assess use of AHT and is estimated as a minimum of one pharmacyfilled prescription for one of the AHT medications within one year of the diagnosis of
BrCa (114).
Chemotherapy
The recommendation from clinical trials is that adjuvant chemotherapy be
initiated within 3 months after surgical intervention (54). Diagnosis-to-chemotherapy
time was shown to be longer for Blacks compared to Whites, and this observed difference
was shown to be higher among women that had their cancer care transferred from other
health care providers to National Comprehensive Cancer Network (NCCN) institutions
after the diagnosis was made (128). The racial disparity was also more marked among
women that were on Medicare compared with women on commercial insurance (128).
A study by Fedewa et al. showed that the mean time from surgery to receipt of
adjuvant chemotherapy was 41 (+24) days (89). In this study, 85% and 96% of patients
received adjuvant chemotherapy within 60 and 90 days, respectively, of surgery (89). The
odds that a Black woman receives late treatment, defined as treatment after 60 days of
receipt of surgery, were 1.6 (95% C.I.: 1.4-1.7) (89) compared to Whites. Apart from
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race, other factors that contributed delayed receipt of chemotherapy were presence of
comorbidities, the type of facility where the treatment was received, insurance status/type
of the patient and stage at diagnosis (89).
Survival Assessments in BrCa Patients
There are different types of outcomes that have been studied in BrCa patients (57,
129). Some of the most studied outcomes are overall survival (OS), BrCa-specific
survival (BSS), BrCa progression-free survival (BPFS), (57, 129) and distant metastasisfree survival (DMFS) (56). Usually, in cancer registry data, vital status and survival
duration are relatively error-free, but the cause of death is sometimes not accurate, as
some studies have shown that the underlying causes of death not coded as BrCa-related
deaths may actually be associated with BrCa treatment–related deaths or are due to BrCa
complications (57, 58). Some studies therefore have preferred OS rather than BSS (57,
58). When it is not feasible to compare treatment types on the basis of OS, BPFS, which
is the time from randomization to progression or death, has been utilized as an acceptable
primary endpoint (129).
Effects of Inadequate or Delayed Treatment on Survival among BrCa Patients
A delay in receipt of BrCa treatment has been associated with reduction in BrCa
survival (74-76). Delays of three or more months have been associated with low 5-year
survival compared with patients who did not experience such a delay (41, 93). Delays
that are less than 90 days have not been generally reported to affect survival in a negative
way (92, 94). However, another study that assessed delay in TPT (with the most frequent
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primary treatment being surgery) using a cutoff point of 30 days did not find a
statistically significant association between TPT and OS (92).
Similar findings in North Carolina showed that diagnosis-to-treatment wait time
did not have an association with OS when patients were diagnosed with early stage BrCa;
however, the association was significant among BrCa patients that were diagnosed at late
stages (8). In this study, the cutoff that to determine late receipt of treatment was 60 days
(8). Women who had late-stage BrCa and received their first course of treatment at/after
60 days after diagnosis had increases of 66% and 85% in their risk for all-cause and
BrCa-specific mortality, respectively (8). Therefore, delays of greater than 90 days were
significantly associated with poor survival in all patients, whereas delays of greater than
60 days were statistically significant among late-stage BrCa patients alone (8, 92, 94).
However, there was also a study that utilized 90 days as a cutoff point to
determine delay in receipt of first definitive treatment for BrCa that did not find a
significant association with OS (94). The reason given for the possible difference
between this study and other studies that found significant associations with OS was the
way in which the delay interval was calculated (94). Whereas other studies utilized onset
of symptoms as the starting point, Brazda et al. utilized date of tissue diagnosis as the
starting point (93, 94, 130).
Effect of Diagnosis-to-Surgery Time on Survival
Delay in breast cancer diagnosis-to-surgery time has been associated with
disparities in breast cancer outcomes (9, 21, 93, 131, 132). BrCa patients who had
surgical intervention 12 weeks after diagnosis or later had worse survival when compared
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with those who had surgery within 1-4 weeks (132). Poorer survival outcomes were
associated with delays greater than 3-6 months among symptomatic women and 6 weeks
among younger women (21, 93). 90% of women that had a diagnosis-to-surgery time of
<2 weeks survived to 5 years, whereas 80% of women that had a diagnosis-to-surgery
time of >6 weeks survived to 5 years (9).
The negative effect of a diagnosis-to-surgery delay is more striking among Black
women, who tended to have public or no insurance and were usually of lower SES (9,
21). When delays from diagnosis-to-surgery time were assessed using cutoffs less than 6
weeks in some studies, mixed results were produced (21, 131, 133). A study that was
carried out among TNBC patients showed that interval to treatment did not affect overall
survival; however, there was a trend towards poor survival among patients with delays
greater than 90 days (131). It has also been shown that longer diagnosis-to-chemotherapy
time is associated with poorer survival outcome (54, 93).
Effect of Diagnosis-to-Radiotherapy/Surgery-to-Radiotherapy Time on Survival
The national guideline consensus by the NIH and ASCO states that BrCa patients
who have high risk for locoregional recurrence should receive PMRT (47-52). Lack of
receipt of radiation therapy following BCS has been shown to lead to increased mortality
among BrCa patients (114, 134). In a North Carolina study among Medicaid-enrolled
women, higher mortality was observed among women who did not get radiotherapy after
BCS (134). These women who did not get radiotherapy had higher odds all-cause and
BrCa-specific mortality of 2.4 and 4.5, respectively (134). However, another study by Shi
et al. found that PMRT used alone was not statistically associated with mortality risk in
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multivariate analyses (135). In terms of the effect of time from surgery to radiotherapy on
survival, a study showed that BrCa patients with an interval greater than 7 months had a
worse 6-year distant metastasis-free survival (56).
Effect of Diagnosis-to-Chemotherapy Time on Survival
BrCa patients who have delay in initiation of chemotherapy have significantly
reduced 10-year survival (136). A study by Downing et al. utilized both traditional
regression analyses and latent class analysis and found that women who had the longest
wait to chemotherapy had the poorest 5-year survival (137). A meta-analysis conducted
utilizing 7 studies showed that a 4-week increase in time to initiation of adjuvant
chemotherapy was associated with significant decrease in OS and DFS (138).
Effect of Diagnosis-to-AHT Time on Survival
Inadequate adherence to AHT has been shown to reduce survival among BrCa
patients (114, 126, 139). A study that assessed the effect of race on mortality outcomes
noted a significant interaction between race and HRP BrCa cases in predicting mortality
(41). The study further showed that Blacks with hormone receptor–negative (HRN) BrCa
had a higher risk of death, with a hazard ratio of 4.0 compared to their White
counterparts. Thus, hormone receptor status serves as an effect modifier in the
relationship between race and mortality (41). Another study found that HRN BrCa
patients still had poorer survival even after accounting for SES and access to healthcare
(55).
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Factors that Affect Diagnosis-to-Treatment Wait Times and Survival Outcomes
(Independent predictors, potential confounders and potential effect modifiers)
Independent predictors of longer diagnosis-to-surgery time that are
socioeconomic in nature are advancing age, Black or Hispanic race, lack of
insurance/Medicaid insurance, low level of education, living in urban areas, higher
number of comorbidities and stage 0 and grade 1 disease (18). Facility-related
independent predictors are high-volume facilities and research/academic facilities (18).
Having to wait longer than 30 days to receive surgical intervention was a predictor of
delay in the receipt of adjuvant chemotherapy greater than 60 days, meaning that one
delay led to another delay (18).
Age
Most BrCa cases occur in women that are above the age of 49 years; however,
BrCa patients that are younger have higher mortality and higher prevalence of factors
leading to poor outcomes (65, 72). Women with BrCa that are younger than 36 years old
are likely to have larger tumors, greater involvement of lymph nodes, higher stage
disease, poorly differentiated tumors and HRN tumors (140).
Factors that lead to poorer outcomes in younger women include larger-sized
tumors, grade, involvement of lymph nodes, less HRP tumors, tumors with poorer grade,
tumors with higher level of recurrences, higher S-phase fractions and higher likelihood of
aneuploidy tumors (72, 140). All these factors lead to worse BrCa-specific and overall
survival among younger BrCa patients (72, 140). In addition, these factors that lead to
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worse survival outcomes among younger women with BrCa are more prevalent among
Black women than White women (72).
Enrolment in Best Chance Network (BCN) Program
The BCN is an early detection program in South Carolina for breast and cervical
cancer (41, 141). Women that are eligible for this program are those that are aged 47-64
years, residents of SC, underserved/underinsured or do not have insurance and are of low
income (less than 200% of the Federal poverty level). This program provides free breast
and cervical cancer screening and started because SC has one of the highest rates of
uninsured women the United States (40, 41, 141). Recruitment into the BCN program is
usually through active search by federally qualified health centers, the South Atlantic
Division, media outlets and through outreaches carried out by the American Cancer
Society. Women that are enrolled in BCN are usually of low socioeconomic status and
are likely to experience treatment delays (41, 141).
In St. Louis, Missouri, an evaluation of BrCa patients referred to the National
Cancer Institute’s designated Comprehensive Cancer Center (NCI-CCC) showed that
women that were referred from a scheme similar to the BCN called the safety net system
experienced greater delays in treatment initiation compared to women that were referred
from private healthcare systems (74-76). The women that were on the safety net systems
also had a higher likelihood of being diagnosed with advanced-stage BrCa (74-76).
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Socioeconomic Status
There are multiple ways in which SES can contribute to BrCa disparities. One
way is that those that are economically disadvantaged are unlikely to take advantage of
screening efforts because of associated costs. This would lead to presentation of
advanced BrCa among this group, thus creating large diagnostic delays and barriers to
comprehensive care (65, 71). Another way that SES leads to racial BrCa disparities is that
Blacks tend to disproportionately receive less of the treatments recommended by various
guidelines, such as locoregional treatment, sentinel lymph node biopsy, reconstruction
treatment for the breast, adjuvant radiotherapy and systemic adjuvant therapy, and they
are less likely to participate in randomized clinical trials (71, 79, 142, 143).
Interestingly, a study in North Carolina showed that poverty was a modifier in the
effect of non-receipt of radiotherapy following BCS, as poor women who did not receive
radiotherapy had 2.4 and 4.5 increased all-cause and BrCa-specific mortality,
respectively, compared with non-poor women (134). This could be because poor women
are likely to have more comorbidity, present with advanced-stage disease and forego
annual surveillance mammography and are more likely to be geographically isolated
from adequate care (134).
One of the ways in which SES has been measured in past studies is utilization of
neighborhood-level, area-level or Census –tract–level poverty (55, 57). In California,
Haji-Jama et al. found that BrCa patients who lived in neighborhoods designated as poor
have worse survival and that Blacks that lived in these poor neighborhoods had a 21%
higher likelihood of worse survival compared to Whites (57). It was also shown that the
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average difference between the annual income of Whites and Blacks in these poor
neighborhoods was $14,575; hence, it is possible that Black uninsured women lacked the
ability to cover out-of-pocket expenses associated with seeking care for BrCa (57, 144).
Hormone Receptor Status and Receipt of Adjuvant Hormonal Therapy
Beyond SES, the disproportionate burden of BrCa experienced by Blacks has also
been partly attributed to biological factors, for which hormone receptor status can serve
as a proxy (55, 65, 67, 105, 124, 145). The incidence rate of TNBC, which is a
determinant of poor prognosis, has been shown to be much higher among Blacks
compared to Whites (71, 79, 124, 145). In addition, the incidence of BrCa among women
aged 45 years and below, which is also associated with poor prognosis, is higher among
Blacks compared to Whites (71, 72, 105).
Additionally, studies have shown that after controlling for SES and stratifying by
stage at diagnosis, there is a still residual disparity in the cancer burden that is
unfavorable to Blacks when compared with Whites (65, 67). This points to the fact that
there are biological factors that contribute to the Black-White disparity in BrCa
outcomes. The role of biological factors has been buttressed by other studies that show
that Black women of African descents (not born in the US) in Britain also have higher
prevalence of TNBC compared with their White counterparts (71, 83, 146, 147).
Insurance Type
Insurance type has been shown to be a contributor to the differences in treatment
noted between Blacks and Whites (72). As a result of the Affordable Care Act (ACA), an
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additional 20 million US citizens obtained health insurance coverage; however,
disparities in health insurance coverage still exist (71, 82). 24% of Blacks are currently
uninsured, whereas that percentage is 8% among Whites (71, 82). A study by Smith et al.
showed that 18% of BrCa patients with no health insurance/public health insurance had a
delay of greater than 6 weeks in diagnosis-to-surgery wait time compared with only 10%
of those with private health insurance (9).
Stage at Diagnosis
A greater proportion of Blacks are diagnosed with later-stage disease (148). The
odds of presenting with late-stage disease among Blacks is 1.5-folds higher than among
Whites (148). Blacks have a 30-60% higher likelihood of being diagnosed with a stage IIIV BrCa when compared to Whites (79).
Type of Surgery
The scheduled type of surgery has also been found to influence the diagnosis-totreatment wait time (74, 128). It has been shown that women who were scheduled for
breast reconstruction surgery experienced increased treatment delays (74, 128). In
addition to experiencing delays from diagnosis-to-treatment wait times, these BrCa
patients have a higher likelihood of having surgical complications, which may lead to
further delays in the initiation of other adjuvant systemic therapies (74, 128, 149, 150).
Marital Status
Mosunjac et al. found that unmarried women with BrCa experienced greater
delays from diagnosis to BCS compared to married women (151). The mean time to BCS
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was 70 days for married women and was 93 days for unmarried women; this difference
was statistically significant (151).
County (Rural versus Urban Status)
Rural versus urban status of BrCa patients has been implicated as a factor that
affects the distribution of late-stage diagnosis (148). Women that lived in nonmetropolitan counties had a higher likelihood of presenting with late-stage BrCa
compared with those who lived in metropolitan counties (148).
Mortality-to-Incidence Ratio (MIR)
The MIR is a unique way to assess racial cancer disparities (5, 10). The MIR is an
important indicator that offers additional useful information beyond what incidence and
mortality rates alone can provide in a study (5, 38). Some studies have utilized MIR
methodology to compare cancer rates (5, 11-13). Wagner et al. previously described
racial cancer disparities and the potential geographical determinants of cancer by
calculating, comparing and mapping MIRs throughout the entire state of Georgia (GA,
United States) and found that Blacks in GA had relatively more fatal cancers than Whites
for all cancer sites evaluated (10). Sunkara et al. also demonstrated a strong linear
relationship between the colorectal cancer MIR and health system rankings across the
various countries evaluated (14).
Mapping of MIRs across SC Department of Health and Environmental Control
(DHEC) health regions has been utilized in past studies in SC (5, 38). SC DHEC
currently defines four health regions for the purpose of planning environmental and
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health programs. A sensitivity analysis described previously by Sunkara et al. (152)
examined the effect of moving across different “denominator years” to vary with the
alignment of the average incidence-to-mortality time interval. The sensitivity analysis
used all combinations of sex and race for cancers involving all anatomic sites. It was
shown that the lines describing the MIR remained parallel, with the rates generally
remaining stable over time across eight different 5-year periods beginning in 1996. This
analysis was performed using incidence data from the SC Central Cancer Registry
(SCCCR) (152).
As a ratio with the mortality rate as the numerator and the incidence rate as the
denominator, the MIR takes on numeric values ranging from 0 to 1. Values closer to 0
indicate more indolent cancers, whereas those closer to 1 indicate more aggressive
cancers. The MIR, which has been shown to be highly insensitive to time-discordant
incidence and mortality (152), does not take into account follow-up time and is not
equivalent to Cox proportional hazards–type survival analysis, which is a truly
multivariate technique that accounts for follow-up time. Similarly, the MIR cannot
account for competing risk.
Computing the MIR
In past studies, in order to compare racial differences in MIRs in SC DHEC health
regions, four categories of MIR were computed (5, 38). First, the MIR for a specific
cancer of interest was computed for Whites nationally (93) (i.e., for the US as a whole
from the United States Cancer Statistics at the Centers for Disease Control and
Prevention) as a reference. The upper limit of Category 1 was the reference; the upper
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limit of Category 2 was 10% higher than the reference; the upper limit of Category 3 was
20% higher than the reference; and Category 4 consisted of MIRs >20% higher than the
reference. This method of categorization and analysis was used previously by Hebert et
al. and Babatunde et al. (5, 38) The defined categories of each DHEC health region were
mapped by race using ArcGIS Version 10.1 (ESRI, Redlands, CA) .
Importance of the MIR in Cancer Surveillance
Using the MIR as a surveillance tool in a past study underscores the point that SC
exhibits more extreme racial differences in cancer incidence, mortality and MIR than
other states or the nation (30-37), and specifically, the MIR helped highlight regions
where this disparity is highest (38). For example, in this past study, Regions 6 and 4 in
SC have the highest MIR disparity, where the MIRs of Blacks are 3.1 and 3.0 times
higher, respectively, than those of Whites. Regions 6 and 4 encompass the Pee Dee
region, which is known for its lower socioeconomic status, rurality and being medically
underserved (5). Additionally, in four of the 12 counties in the Pee Dee regions (Dillon,
Lee, Marlboro and Williamsburg), over 40% of adults report a BMI of 30 or more (153).
Similarly, the percentage of adults aged 20 and over reporting no leisure-time physical
activity was greater than 30% in seven counties (Chesterfield, Darlington, Dillon, Lee,
Marion, Marlboro and Sumter) out the 12 counties in the Pee Dee region (153). Urban
centers with major hospital systems such as Charleston (Region 7), Columbia (Region 3),
Greenville and Spartanburg (Region 2) may be responsible for the relatively smaller MIR
disparities seen in Regions 2 and 7 in the previous study (38).
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The MIR serves as a population-based approximation of fatality (1/survival) given
incidence by stabilizing the incidence and mortality differences across cancer sites and
racial groups (5, 10, 38). One of the advantages of MIR analyses lies in the fact that it
gives researchers the opportunity to use combined data over many years with minimal
data request protocol; this makes MIR estimates more stable (38). Data used for MIR
analyses usually help mitigate problems associated with migration of patients in and out
of a jurisdiction/state. This is because of the interjurisdictional exchange agreements
between states to capture out-of-state deaths of residents. Also, MIR analyses usually
involve a population-based study of the entire population of patients, whereby incidence
and mortality data represent >94% of all cancer cases. Thus, the study is virtually devoid
of selection bias, a common problem associated with such studies. Additionally, the MIR
is cheap and easy to compute from existing relatively complete data. The MIR can be
used as a surrogate measure for a more expensive and time-consuming survival studies
(38).
Drawbacks of the MIR Necessitating Need for a Sensitivity Analyses
A main drawback of the MIR, however, is that there is no way to compute
censoring and loss to follow up. It is also not possible to adjust for covariates such as
treatment, comorbidities or individual socioeconomic status in the analysis. Another
weakness is that the relationship between the numerator (mortality) and the denominator
(incidence) may not be direct because persons diagnosed of with cancer may not die of
cancer and persons who die after the diagnosis of cancer may survive for varying lengths
of time, which cannot be accounted for by the MIR (84). A sensitivity analysis comparing
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regional survival with MIR analyses will therefore validate the use of the MIR in
surveillance.

36

CHAPTER 3

METHODS
Data Source
This study was a retrospective cohort study (2002 to 2009) that included data on
all BrCa patients derived from linked files from the SCCCR and Office of Revenue and
Fiscal Affairs (which maintains the administrative medical claims data for the South
Carolina Public Employee Benefits plan and Medicaid). The study was exempt from IRB
review by the University of South Carolina IRB. All newly diagnosed cases of cancers
were collected by SCCCR, which is a population-based system in SC. Data in the
SCCCR included information on demographics, diagnosis date, cancer location and
histology, treatment and overall survival. (38) All incident cancer cases were required by
law to be reported to SCCCR, a resource established with funding from an award from
the National Program of Cancer Registries (NPCR) in 1994. Enabling legislation from
the SC General Assembly was enacted in 1996. Data are collected by SCCCR on all
cancers, both in-situ and invasive, from hospitals, pathology laboratories, freestanding
treatment centers and physician offices. The only exceptions are in situ forms of cervical
cancer and invasive forms of basal and squamous cell skin cancers of non-genital sites.
The SCCCR from which we derived the data for this analysis has a history of
receiving the highest/gold rating for data completeness (>94%), timeliness and data
quality from the North American Association of Central Cancer Registries and NPCR.
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SCCCR is a member of the CDC National Interstate Data Exchange System (N-IDEAS),
such that any member state may share resident incident cases with others to ensure the
completeness of incident cancer data. Additionally, there was geocoding of all cancer
cases and cancer deaths in the state of SC.
The SC Revenue and Fiscal Affairs Office (RFA) is an independent agency that
houses administrative claims data from both SC State Employee Health Plan and SC
Medicaid plan members. The RFA developed a series of algorithms using various
combinations of personal identifiers to create its own unique identifier, enabling
statistical staff to “link across” multiple providers and settings. Hence, it allowed for
linkages while protecting the confidentiality of the client. The SC Revenue and Fiscal
Affairs Office and SC Central Cancer Registry frequently work together to complete data
linkage requests for researchers in SC. All BrCA cases between the time period of 2002
to 2010 who met eligibility criteria (that could be ascertained from their files) were given
to RFA. Then RFA matched to determine which cases linked and further met our
eligibility criteria (that required claims data to ascertain). This resulted in the 2155 cases.
This resulting combined dataset was used to conduct all analyses.
Data Linkage and Security
Linkages were made with 3 personal identifiers: name, date of birth and social
security number. As per protocol, these linkages were performed by RFA in partnership
with SCCCR. Because of data security issues, only the final de-identified dataset was
released to study personnel and investigators for analysis. The key to the de-identified
dataset was retained by RFA in the event that further data clarifications are needed from
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the primary record. Once the de-identified data were received, the study data manager
performed routine outlier and logic checks. Any improbable values were verified with
RFA or SCCCR and rectified where possible. To create an analytic dataset, we utilized
datasets from the RFA (Medicaid and State Health Plan), BCN and SCCCR to create an
extensive look at breast cancer treatment in South Carolina for Black and White women.
Data acquisitions were linked through the aforementioned departments by the RFA, and
only a study participant number was assigned to each person for analysis by investigators.
Because the final dataset was completely de-identified, the investigators have no linkages
to the original identifiable patient contact information and will be referred to via a study
participant number only.
Variables
Aim 1
For aim 1, the main predictor variable was race of the BrCa cases, dichotomized
as Black or White. The main outcome variable was time from diagnosis to various forms
of treatment, i.e., surgery, AHT, chemotherapy and radiotherapy. Outcome variables
were treated as numeric variable (days) or dichotomized variables (early and late)
depending on whether they met the assumptions for a linear model. Variables that were
considered as covariates or effect modifiers are age, marital status, county of residence
(whether rural or urban), year of diagnosis, hormone receptor status, enrolment in BCN
(dichotomized as yes or no), stage of BrCa at diagnosis and grade of BrCa at diagnosis.
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Aim 2
For aim 2, the main predictor variable was race of the BrCa cases, dichotomized
as Black or White. The main outcome variable was time until death. Variables that were
considered as covariates or effect modifiers are age, marital status, county of residence,
year of diagnosis, hormone receptor status, enrolment in BCN (dichotomized as yes or
no), sta ge of BrCa at diagnosis and grade of BrCa at diagnosis.
Outcome Variables. Overall and breast cancer mortality: We utilized vital status,
total survival time, and BrCA cause of death (yes/no) for this investigation. From cause
of death information, we were able to examine both all-cause/overall mortality, as well as
BrCa-specific mortality.
For survival analyses, the main predictor variable was race stratified by region,
categorized as Upstate, Midlands, Low Country and Pee Dee. Survival analyses were
carried out in each of the four regions and ranked using hazard ratios. Possible covariates
or effect modifiers are age, marital status, county of residence, year of diagnosis,
hormone receptor status, stage of BrCa at diagnosis, grade of BrCa at diagnosis, race of
the BrCa cases dichotomized as Black or White, receipt of AHT dichotomized as yes/no,
early/late receipt of AHT, and BCN dichotomized as yes/no.
Aim 3
This study described BrCA disparities in SC among Blacks and Whites using
MIRs by race for the four health regions and by 46 counties within SC. We proceeded to
rank the four health regions by race from the worst to the best using MIRs. MIR were
computed from Cancer incidence and mortality data which were obtained from the SC
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Community Access Network (SCAN) for 1996 to 2016 (county maps) and 2002 to 2010
(regional maps). In order to compare racial differences in BrCa MIRs in the four SC
DHEC health regions, seven categories (for county maps) of BrCa MIRs were defined.
First, the MIR were computed for Whites nationally (93) (i.e., for the US from the United
States Cancer Statistics at the Centers for Disease Control and Prevention) as a reference.
The upper limit for Category 1 was the reference; the upper limit of Category 2 was 10%
higher than the reference; the upper limit of Category 3 was 20% higher than the
reference; the upper limit of category 4 was 30% higher than the reference; the upper
limit of category 5 was 40% higher than the reference; the upper limit of category 6 was
50% higher than the reference and Category 7 consisted of MIRs >50% higher than the
reference. This method of categorization and analysis was adapted from a previous study
by Hebert et al. and Babatunde et al. (5, 38)
Project Design and Analysis Plan
Aim 1
Overall goal: We assessed racial disparities in treatment delays among
patients diagnosed with BrCa.
Approaches of the dissertation research project: The main outcome variable
were diagnosis-to-treatment time (overall and by various treatment modalities, i.e.,
surgery, AHT, chemotherapy and radiotherapy), which were defined as the interval
between the date of diagnosis and the date of first treatment for the four forms of
treatment. The main exposure variable was the patient’s race (White vs Black). Race will
be determined by the Central Cancer Registry Records, which are based on self-reported
41

data collected by hospitals and providers. Student’s t-test with a significance level of 0.05
were used to assess differences in diagnosis-to-treatment times by patient’s race. The
outcome variables were checked for normality and other linearity assumptions. If
linearity assumptions were met, a generalized linear model will be used to compute leastsquare means and 95% C.I.s for each dependent variable (surgery wait time, AHT wait
time, radiation wait time and chemotherapy wait time) comparing those Blacks with
Whites after adjustment for age, marital status, county of residence, year of diagnosis,
hormone receptor status, enrolment in BCN (dichotomized as yes or no), stage of BrCa at
diagnosis and grade of BrCa at diagnosis. Observations with elevated studentized
residuals and Cook’s D values were removed from the analyses.
When linearity assumptions were not met, we dichotomized the four outcomes
into early and late receipt of treatment using the cutoff as determined from the median in
the univariate analyses of the outcome variables. When this latter option was used, we
fitted a logistic regression model to compare early to delayed receipt of treatments with
the goal of identifying important predictors of treatment delay for each dependent
variable (surgery, AHT, radiation and chemotherapy) comparing Blacks with Whites
after adjustment for age, marital status, county of residence, year of diagnosis, hormone
receptor status, enrolment in BCN (dichotomized as yes or no), stage of BrCa at
diagnosis and grade of BrCa at diagnosis.
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Aim 2
Overall goal: Identification of patient- and neighborhood-level predictors of dissimilarity
in BrCa-related survival among Blacks utilizing multilevel (state and regional) survival
models among BrCa patients.
Approaches of the dissertation research project:
For aim 2, Kaplan-Meier survival curves were used to assess BrCa-specific and
all-cause survival at the state and regional levels. The relationships between race,
mortality rates, diagnosis-to-treatment times and all covariates will be assessed using the
Cox proportional-hazards model. A backward elimination process was utilized to obtain
the best model. Individual-level, (30) and health region–level (i.e., four health regions
comprised of contiguous counties located in SC) (38) factors have been shown to make
contributions to the pervading cancer disparities experienced by minority groups. A
combination of geospatial methods and multilevel survival modeling helped to
objectively identify individual-level and health region–level predictors of survival. The
use of GIS and related spatial methodologies has the potential to identify
environmental/neighborhood predictors of health outcomes, and this technique is
increasing in popularity. (154, 155) Predictor variables/covariates that were considered
with survival analyses are age, marital status, county of residence (urban or rural), year of
diagnosis, hormone receptor status, enrolment in BCN (dichotomized as yes or no), stage
of BrCa at diagnosis and grade of BrCa at diagnosis.
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Aim 3
Overall goal: To compare MIR methodology with survival methodology in assessing
racial BrCa disparities over the eight-year period across the four health regions in SC.
Rationale:
Survival analysis: Overall survival rates was estimated using Kaplan-Meier
techniques. 5-year and 12-year overall survival and BrCA specific survival were
estimated and corresponding 95% confidence intervals were calculated. Cox Proportional
hazard models were used to evaluate the impact of race on overall survival while
adjusting for potential confounders.

MIR: BrCa MIRs by race (Black vs. White) will be computed for years 20022010. Years 2002 to 2010 will be utilized to mirror the years of registry data that were
obtained for the survival analyses. The age-adjusted incidence and mortality rates will
first be calculated using incidence and mortality data from SCCCR. MIRs will be
stratified by race, specifically Blacks versus Whites. As a ratio with the mortality rate in
the numerator and the incidence rate in the denominator, the MIR takes on values ranging
from 0 to 1. Values closer to 0 indicate more indolent cancers, whereas those closer to 1
indicate more aggressive cancers. The MIR, which has been shown to be highly
insensitive to time-discordant incidence and mortality (152), does not take into account
follow-up time and is not equivalent to Cox proportional hazards-type survival analysis,
which is a truly multivariate technique that accounts for follow-up time.
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Computing the MIR
This study described BrCA disparities in SC among Blacks and Whites using
MIRs by race for the four health regions and by 46 counties within SC. We proceeded to
rank the four health regions by race from the worst to the best using MIRs. MIR were
computed from Cancer incidence and mortality data which were obtained from the SC
Community Access Network (SCAN) for 1996 to 2016 (county maps) and 2002 to 2010
(regional maps). In order to compare racial differences in BrCa MIRs in the four SC
DHEC health regions, seven categories (for county maps) of BrCa MIRs were defined.
First, the MIR were computed for Whites nationally (93) (i.e., for the US from the United
States Cancer Statistics at the Centers for Disease Control and Prevention) as a reference.
The upper limit for Category 1 was the reference; the upper limit of Category 2 was 10%
higher than the reference; the upper limit of Category 3 was 20% higher than the
reference; the upper limit of category 4 was 30% higher than the reference; the upper
limit of category 5 was 40% higher than the reference; the upper limit of category 6 was
50% higher than the reference and Category 7 consisted of MIRs >50% higher than the
reference. This method of categorization and analysis was adapted from a previous study
by Hebert et al. and Babatunde et al. (5, 38)
Comparison of MIR and survival
The health region–specific MIRs by race were compared with survival by race in
each health region to see if the MIR is a true approximation of survival. The hypothesis is
that the median survival time will be a mirror image of the MIR for each of the eight
health regions in SC. All statistical analyses will be performed using Statistical Analysis
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Systems software, version 9.2 (SAS Inc., Cary, NC). All hypothesis testing will be 2sided with a p<0.05 level of statistical significance.
A study that I led in the past (38) utilizing MIRs as a proxy for survival under the
supervision of my mentor showed that MIR helped highlight regions where endometrial
cancer (EC) disparity was highest. For example, Regions 6 and 4 have the highest MIR
disparity in EC, where the MIRs of Blacks are 3.1 and 3.0 times higher, respectively, than
those of Whites. In SC, Regions 6 and 4 encompass the Pee Dee region, which is known
for its lower socioeconomic status, rurality and being medically underserved (5).
Additionally, in four of the 12 counties in the Pee Dee region (Dillon, Lee, Marlboro and
Williamsburg), over 40% of adults report a BMI of 30 or more (153). Similarly, the
percentage of adults aged 20 and over reporting no leisure-time physical activity was
greater than 30% in seven counties (Chesterfield, Darlington, Dillon, Lee, Marion,
Marlboro and Sumter) out of the 12 counties in the Pee Dee region (153). Also in this
study, (38) urban centers with major hospital systems such as Charleston (Region 7),
Columbia (Region 3), Greenville and Spartanburg (Region 2) may be responsible for the
relatively smaller MIR disparities seen in Regions 2 and
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CHAPTER 4

RACIAL DISPARITIES AND DIAGNOSIS-TO-TREATMENT TIME
AMONG PATIENTS DIAGNOSED WITH BREAST CANCER IN
SOUTH CAROLINA

Introduction
A delay in the commencement of treatment has been hypothesized as one of the
possible reasons for the higher mortality among Blacks despite lower incidence over the
years. (3) Survival studies have shown that a treatment delay is associated with less
favorable survival among BrCA cases. (3, 8, 9) Although the Black-White disparity in
BrCA mortality is seen both at the national level and in SC, the disparity is of a higher
magnitude in SC (30, 40, 41): mortality among White BrCA patients is 7% lower in SC
compared to the national average and is 29% higher among Blacks in SC (30, 40, 41).
Also, in SC, mortality from BrCA amongst Blacks is greater than 60% than that of
Whites (5). Studies also show that Blacks experience worse mortality outcomes after
matching for known prognostic factors, and this finding has persisted over time (42-45).
The various forms of delay that Black women diagnosed with BrCA experience
are related to diagnosis, (19) as well as time to surgery, (3, 20, 21) chemotherapy, (4, 22,
23) adjuvant hormonal therapy, (24-26) and all forms of treatment combined. (27, 28)
Documented factors that affect delay in treatment among BrCA by race include age, (28)
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hospital type, (23) trust in oncologists and communication with physicians. (4) Delays in
adjuvant therapy among BrCA patients have been shown to worsen survival (18, 29) and
increase patient anxiety. (18)
Although various studies in other states consistently show that Black women with
BrCA experience delays in receipt of surgery, chemotherapy, AHT and radiation, (3, 4,
19-23, 27, 28) this has not been examined in SC, which has a high representation of
minority and rural populations. SC has well-documented inter-racial differences in cancer
incidence and mortality (30-38). In addition, the possible factors that affect racial
disparity in treatment delays in SC have not been examined.
The aim of this study was to assess racial disparities in BrCA treatment time in
South Carolina (SC) by comparing diagnosis-to-treatment times for the various forms of
treatment in Blacks and Whites with BrCA and to assess related effect modifiers. We
hypothesize that the diagnosis-to-treatment wait time is higher among Blacks compared
to Whites for all BrCA treatment types in SC.

Methods
Data Source
This is a retrospective cohort study (2002 to 2010) that included data on all BrCA
patients derived from linked files from the SC Central Cancer Registry (SCCCR) and
Office of Revenue and Fiscal Affairs (which maintains the administrative medical claims
data for the South Carolina Public Employee Benefits plan and Medicaid). The dataset
was deidentified, hence the study was exempt from IRB review by the University of
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South Carolina’s IRB. All newly diagnosed cancer cases are collected by SCCCR, which
is a population-based cancer registry in SC. Data in the SCCCR include information on
demographics, diagnosis date, cancer location and histology, treatment and overall
survival. (38)
The SCCCR has a history of receiving the highest/gold rating for data
completeness (>94%), timeliness and data quality from the North American Association
of Central Cancer Registries and NPCR. SCCCR is a member of the CDC National
Interstate Data Exchange System (N-IDEAS), such that any member state may share
resident incident cases with others to ensure the completeness of incident cancer data.
Additionally, there is geocoding of all cancer cases and cancer deaths in the state of SC.
The SC Revenue and Fiscal Affairs Office (RFA) developed a series of
algorithms using various combinations of personal identifiers to create its own unique
identifier, enabling statistical staff to “link across” multiple providers and settings.
Hence, it allows for linkages while protecting the confidentiality of the client. All BrCA
cases between the time period of 2002 to 2010 who met eligibility criteria (that could be
ascertained from their files) were given to RFA. Then RFA matched to determine which
cases linked and further met our eligibility criteria (that required claims data to ascertain).
This resulted in the 2155 cases. This resulting combined dataset was used to conduct all
analyses.
Because of data security issues, only the final de-identified dataset was released to
study personnel and investigators for analysis. The key to the de-identified dataset was
retained by RFA if further data clarifications are needed from the primary record. Once
the de-identified data was received, there was a performance of routine outlier and logic
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checks. Any improbable values were verified with RFA or SCCCR and rectified where
possible. To create an analytic dataset, we utilized datasets from the RFA (Medicaid and
State Health Plan), Best Chance Network (BCN) and SCCCR to create an extensive look
at BrCA treatment in South Carolina for Black and White women. The BCN is an early
detection program in South Carolina for breast and cervical cancer (41, 141). Women that
are eligible for this program are those that are aged 47-64 years, residents of SC,
underserved/underinsured or do not have insurance and are of low income (less than
200% of the Federal poverty level).
Inclusion and Exclusion Criteria
To qualify for inclusion in the analytic sample, the BrCA cases were those
diagnosed as a first primary cancer between 2002 and 2010, had a form of insurance
(either Medicaid or state health plan) at the time of diagnosis and had 36 months of
continuous eligibility on the insurance. This was to ensure that treatment data was
available for at least 36 months post diagnosis for each case.
Variables
The main predictor variable was race, dichotomized as Black or White. Race
variable was self-reported as determined by the SCCCR records. The main outcome
variable was time from diagnosis to receipt of first treatment for various forms of
treatment, i.e., surgery, AHT, chemotherapy and radiotherapy. The first treatment
received was determined and the number of days from diagnosis to the treatment
modality was also determined. New variables designated diagnosis-to-treatment time for
each of the four forms of treatment were created. Outcome variable for AHT was treated
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as numeric because records met the assumptions for a linear model using skewness and
kurtosis of -2 to +2 when assessed by race.
The outcome variable for chemotherapy, radiotherapy and surgery were
dichotomized variables (early and late) because they did not meet the assumptions for
linear models. The cut-off for dichotomization was based on the median for the
distribution which was 22, 60, and 60 for surgery, chemotherapy and post-surgery
radiotherapy respectively. Variables that were considered as covariates or effect
modifiers were age, marital status, urban vs. rural designation (based on rural urban
commuting codes/RUCA 2003), year of diagnosis (2002-2004, 2005-2007, 2008-2010),
hormone receptor status (positive or negative), enrollment in BCN (dichotomized as yes
or no), stage of BrCA at diagnosis (insitu, local, regional, or distant), grade of BrCA at
diagnosis (well differentiated, moderately differentiated, poorly differentiated and
undifferentiated) network distance to health care provider (in miles), definitive surgery
type (lumpectomy or mastectomy), early/late surgery (early or late), and insurance
provider (provider 1 or provider 2). One of the health insurance provider categories was
Medicaid, while the other one was private (State Employee Health Plan); the specific
payer source was not identified in the analytic dataset as per data use agreements
specified by the payers.
Analysis
A generalized linear model was used to compute least-square means and 95% CIs
for AHT (dependent variable that met linear assumptions) comparing Blacks with Whites
after adjustment for age, urban versus rural designation, year of diagnosis, hormone
receptor status, enrollment in BCN (dichotomized as yes or no), stage of BrCA at
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diagnosis, and distance to providers. In assessing the relationship between race and time
to AHT, we assessed for the presence of effect modifiers and marital status, being
enrolled in BCN, late surgery and insurance providers were identified as effect modifiers:
the multivariable generalized linear model therefore was stratified by the effect modifier
variables.
The variables that did not meet linearity assumptions (chemotherapy, radiotherapy
and surgery), were dichotomized into early and late receipt of treatment using 22 days for
surgery, 60 days for chemotherapy and post-surgery radiation. Two-way interactions
were assessed between the all predictor variables and race. There was statistically
significant interaction between race and marital status, race and urbanicity, and race and
distance. The multivariable logistic model was stratified by the effect modifier variables
and each model was adjusted for age, year of diagnosis, hormone-receptor status, stage,
grade, and being in BCN.
In assessing the relationship between race and time to post-surgery radiation, the
identified effect modifiers were age, hormone-receptor status and insurance provider. The
multivariable logistic model was stratified by the effect modifier variables and each
model was adjusted for marital status, urban status, year of diagnosis, stage, grade,
distance to providers and early/late receipt of surgery. In assessing the relationship
between race and time to chemotherapy, the identified effect modifiers were urban status
and early/late surgery. The multivariable logistic model was stratified by the effect
modifier variables and each model was adjusted for age, marital status, diagnosis year,
stage, grade, distance, insurance provider, and definitive surgery type.
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Results
Descriptive statistics for this study sample are shown in Table 1. Overall, there
were 2155 cases of BrCA patients of which the majority were Whites (1557, 72.25%). In
bivariate analyses, there were significant differences between Blacks and Whites in age,
rural/urban status, year of diagnosis, hormone receptor status, cancer grade, cancer stage
and insurance provider. Blacks were more likely to be in age group 45-54 (45.99%) while
whites were more likely to be in age group 55-64 years (41.88%). Blacks were more
likely to be unmarried (57.17%) compared to Whites (29.95%). The proportion of Whites
that live in urban area (79.13% vs 67.22%) and have hormone receptor positive cancer
(81.03% vs 68.89%) is higher among whites compared to blacks. More blacks were
participants in BCN compared to Whites (9.87% compared with 3.85%).
Table 2 presents diagnosis to hormone treatment times by marital status, being in
BCN, early surgery and insurance provider. Multivariable generalized linear model
regression analysis showed that the least square means from diagnosis to surgery were
statistically increased among Blacks that were not married (54 days), Blacks that were
not on BCN (36 days), Blacks that had late surgery later than 30 days after diagnosis (42
days), Blacks that had surgery later than 60 days after diagnosis (63 days) and Blacks that
were on insurance provider 1 (46 days) adjusting for age, diagnosis year, hormonereceptor status, stage, grade, urban status, and distance to provider.
Multivariable logistic regression that adjusted for 8 variables (age, year of
diagnosis, hormone receptor status, cancer stage, cancer grade, being in BCN, definitive
surgery type and insurance provider) showed that the odds of late receipt of surgery was
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1.96 (95% CI: 1.38-2.79) among unmarried black women compared with unmarried
white women; 1.89 (95% CI: 1.32-2.71) among blacks who lived <=10 miles to health
providers compared to whites who lived <=10 miles; and 1.40 (95% CI: 1.08-1.82)
among blacks who live in urban areas compared with white women who lived in urban
areas (Table 3).
Table 4 presented the results of race by late receipt of post-surgery radiation
stratified by age, hormone receptor status and insurance provider in which each model
adjusted for marital status, urban status, diagnosis year, stage, grade, distance, definitive
surgery type and receipt of early/late surgery. The only significant finding upon
multivariable modeling was that black women were less likely to receive late postsurgery radiation (OR: 0.30; CI: 0.10-0.93) compared to white women which implies that
the odds of white women with hormone receptor negative BrCA receiving late postsurgery radiation was 3.3 (CI: 1.07-10.28).
Table 5 presented the results of race by late receipt of chemotherapy stratified by
urban status and late/early surgery. Each model adjusted for age, marital status, diagnosis
year, stage, grade, distance, insurance provider and definitive surgery type. Multivariate
analysis did not show any significant finding.

Discussion
This study demonstrated that there was a longer diagnosis-to-treatment time for
all treatment modalities for Blacks when compared with Whites. Late receipt of AHT was
higher among blacks that were unmarried, received late surgery, and not a participant of
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the BCN. We also found that late receipt of surgery was higher among blacks that were
unmarried, lived in urban areas and those who lived less than 10 miles to their health care
provider. The only sub-group where whites had a later receipt of treatment was for postsurgery radiation among hormone receptor negative BrCA patients. In addition to
showing that there were longer diagnosis-to-treatment time in which has been
demonstrated from previous studies, (18, 22, 26, 74, 128) we were able to add the
following to the racial disparity discussion: the impact of being unmarried, living in
urban areas, enrolment in BCN, and distance on late receipt of treatment. This study also
showed the positive relationship between late receipt of surgery and time to AHT
demonstrating that those who are late to receive one form of treatment are likely to be
late at the receipt at other forms of treatment. The use of the findings in this paper has the
potential to further enhance the understanding of navigation of health care process and
strengthen navigation efforts aimed at linking women with BrCA to care especially
among blacks thereby reducing racial disparities.
In analysing the longer diagnosis-to-treatment time in receipt of AHT, this study
had a cohort that contained patients on Medicaid and patients on a private payor health
plan which made the findings more representative compared with previous studies that
was among Medicaid only or private insurance only and which had different findings in
racial disparities (6, 26). These previous studies showed that the association between race
and commencement of AHT is not well elucidated and appears to be incompletely
studied and controversial; thus, our work provided a further understanding of the
relationship. In North Carolina (NC), statistically significant racial disparity in
commencement of AHT was demonstrated: Blacks were less likely to commence AHT,
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and this racial disparity was more pronounced among the subpopulation of patients that
did not receive chemotherapy. (26) However, in a previous study in SC, there was no
racial difference found between Blacks and Whites in the commencement and early use
of AHT, but further analysis showed that receipt of chemotherapy/radiation was
independently associated with commencement/early use of AHT. (6) In the study
described above in NC, the BrCA cases were privately insured (26); however, in the
previous study in SC (6), the BrCA cases were on Medicaid insurance. Because our study
had both groups of insurance providers, it provided a further understanding showing that
racial disparities existed in receipt of AHT with blacks entering care at least about 17
days later after adjustments were made for age, year of diagnosis, stage, grade, urban
status and distance to provider.
A study that used three cutoff points (30, 60, 90 days) to define a diagnosis-tosurgery delay showed that Black women were more likely to experience delays compared
to White women, and this association was independent of health insurance status, age at
diagnosis and cancer stage at diagnosis (46). Additionally, studies have shown that after
controlling for socio-economic status and stratifying by stage at diagnosis, there is still
residual disparity in the cancer burden that is unfavorable to Blacks when compared with
Whites (65, 67). Our study provided an additional insight into this topic by assessing
other factors that influence a longer diagnosis-to-treatment time for surgery apart from
health insurance, age at diagnosis and cancer stage at diagnosis (21). Our study showed
that unmarried black women were more likely to have a longer diagnosis-to-treatment
time in receipt of surgery and AHT. Our finding is like that of Mosunjac et al. which
found that unmarried women with BrCA experienced greater delays from diagnosis to
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breast conserving surgery compared to married women (151). The mean time to BCS was
70 days for married women and was 93 days for unmarried women; this difference was
statistically significant (151). Our study also added to the literature with our finding that
among women who lived in urban areas and who lived less than 10 miles to their health
care providers, black women were likely to receive late surgery.
The diagnosis-to-treatment interval is an important quality measure that is
recognized by the National Accreditation Program for Breast Centers (NAPBC), the
American Society of Breast Surgeons (ASBS) and the National Quality Measures for
Breast Care (NQMBC) (94-96). The NAPBC, ASBC and NQMBC all serve to validate
BrCA care rendered by hospitals (94-96). Although, there has been no formal agreement
on what constitutes an acceptable delay in terms of quality of BrCA care measures (9496), our study demonstrated racial disparities in diagnosis to treatment in the receipt of
surgery and AHT. Another reason that the diagnosis-to-treatment wait time is important
is that studies have shown one of the most overwhelming, distressing and anxietyproducing periods for BrCA patients is the waiting time between an abnormal
mammogram and treatment initiation (94, 97). Our study therefore helped to identify
subgroups of BrCA patients that may benefit from more intensive navigation to care in
order to shorten the diagnosis-to-treatment times for various BrCA patients.
Our finding that late surgery predicted late receipt of AHT is similar to previous
studies where having to wait longer than 30 days to receive surgical intervention was a
predictor of longer diagnosis-to-treatment time in the receipt of adjuvant chemotherapy
greater than 60 days, meaning that one delay led to another delay (18). This is a finding
that has a potential implication for navigation programs that perhaps additional efforts
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need to be planned to link people who have already experienced one form of delay along
the care continuum, so they do not continue to be delayed in other forms of treatment that
has the potential to enhance survival.
Our findings show that Blacks who were not enrolled in the BCN experienced a
longer diagnosis-to-treatment time in receipt of surgery. The BCN is an early detection
program in South Carolina for breast and cervical cancer (41, 141). Women that are
eligible for this program are those that are aged 47-64 years, residents of SC,
underserved/underinsured or do not have insurance and are of low income (less than
200% of the Federal poverty level). This program provides free breast and cervical cancer
screening and started because SC has one of the highest rates of uninsured women the
United States (40, 41, 141). Recruitment into the BCN program is usually through active
search by federally qualified health centers, the South Atlantic Division, media outlets
and through outreaches carried out by the American Cancer Society. Women that are
enrolled in BCN are usually of low socioeconomic status and are likely to experience
longer diagnosis-to-treatment time (41, 141). In St. Louis, Missouri, an evaluation of
BrCA patients referred to the National Cancer Institute’s designated Comprehensive
Cancer Center (NCI-CCC) showed that women that were referred from a scheme similar
to the BCN called the safety net system experienced longer diagnosis-to-treatment time in
treatment initiation compared to women that were referred from private healthcare
systems (74-76). The women that were on the safety net systems also had a higher
likelihood of being diagnosed with advanced-stage BrCA (74-76). Since, our findings
showed that there is a longer diagnosis-to-treatment time in receipt of AHT between
Blacks and Whites that are not on BCN but no difference between Blacks and Whites on
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BCN, it therefore suggests that, perhaps the BCN program in SC is helping to close the
racial disparity gap between Whites and Blacks or those who are on BCN have other
factors that is driving the racial disparities. This will benefit from future studies.
One strength of this study is the availability of a wide range of effect modifiers
and covariates that were utilized in the analysis. To our knowledge, this is the first study
that assessed all 4 treatment modalities among both privately and publicly insured
patients using both multivariate logistic regressions and multivariate generalized linear
models (depending on distribution of outcome data) with specific emphasis on assessing
effect modifiers in SC, which has a high representation of minority and rural populations.
Our study was also able to analyze the role of distance to health care provider in late
receipt of treatment. Limitations of this study include inability to study biological factors
that contribute to the Black-White disparity in BrCA outcomes. The role of biological
factors has been buttressed by other studies that show that Black women of African
descents (not born in the US) in Britain also have higher prevalence of triple negative
BrCA compared with their White counterparts (71, 83, 146, 147).
In conclusion, late receipt of AHT was higher among blacks that were unmarried,
received late surgery, and not a participant in BCN. We also found that late receipt of
surgery was higher among blacks that were unmarried, lived in urban areas and those
who lived less than 10 miles to their health care provider. There is a longer diagnosis-totreatment time in receipt of AHT between blacks and white that are not on BCN but no
difference between blacks and white on BCN, it therefore suggests that, perhaps the BCN
is helping to close the racial disparity gap between whites and blacks or those who are on
BCN have other factors that is driving the racial disparities. The relationship between
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being on BCN and diagnosis-to-treatment time in receipt on AHT will benefit from future
studies as it will be important to understand the reason for the longer time among those
not on BCN. To improve overall timely receipt of AHT, efforts need to be directed at
Black BrCA patients that are not married, not on BCN and received late surgery. To
improve overall timely receipt of surgery, efforts need to be directed at Black BrCA
patients that are not married, lived in urban areas and lived <=10 miles from health
providers.
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Table 4.1 Summary of patients’ characteristics by race
N (%)
Total
(N=2155)
51.20(7.20)

N (%)
White
N=1557
(72.25)
51.60(6.99)

N (%)
Black
N=598
(27.75)
50.17(7.63)

Under 45
years old
45-54 years
old
55-64 years
old

386(17.91)

256(16.44)

130(21.74)

924(42.88)

649(41.68)

275(45.99)

845(39.21)

652(41.88)

193(32.27)

Marital status

Not married
Married

751(34.85)
1256(58.28)

436(29.95)
1020(70.05)

315(57.17)
236(42.83)

<0.01

Rural/Urban
status

Urban

1634(75.82)

1232(79.13)

402(67.22)

<0.01

Rural

521(24.18)

325(20.87)

196(32.78)

2002-2004

611(28.35)

452(29.03)

159(26.59)

2005-2007
2008-2010

693(32.16)
851(39.49)

518(33.27)
587(37.70)

175(29.26)
264(44.15)

Positive

926(42.97)

709(81.03)

217(68.89)

Negative

264(12.25)

166(18.97)

98(31.11)

In-situ

422(21.72)

299(19.34)

123(20.78)

Local
Regional
Distant

1013(47.01)
657(30.49)
46(2.13)

741(47.93)
470(30.40)
36(2.33)

272(45.95)
187(31.59)
10(1.69)

I
II
III
IV

392(18.19)
785(36.43)
749(34.76)
32(1.48)

300(21.29)
608(43.15)
479(34.00)
22(1.56)

92(16.76)
177(32.24)
270(49.18)
10(1.82)

Characteristic

Age
(mean+SD)
Age categories

Year of
diagnosis

Hormone
receptor status
Stage at
Diagnosis

Cancer grade
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P

<0.01
<0.01

0.02

<0.01

0.68

<0.01

Best Chance
Network
Insurance
provider
Average
distance to
AHT provider
(miles)

<0.01

Yes

119(5.52)

60(3.85)

59(9.87)

No

2036(94.48)

1497(96.15)

539(90.13)

1

1640(76.10)

1285(82.34)

358(59.87)

<0.01

2

515(23.90)
7.25+17.00

275(17.66)
7.19+18.09

240(40.13)
7.44+13.40

0.79

Average
distance to
Surgery
provider
(miles)

19.89+23.54 19.99+25.03 19.60+19.11 0.72

Average
distance to
Radiation
provider
(miles)

18.64+18.54 18.19+18.30 19.75+19.11 0.17

Average
distance to
Chemotherapy
provider
(miles)

20.55+20.68 19.69+20.27 22.58+21.48 0.03
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Days till hormone treatment

Adjusted least square means for diagnosis to
hormone treatment*
195
190

189

185
180
175

172

170
165
160

Black

White

Race

Figure 4.1: Adjusted least square means for diagnosis to hormone treatment
showing increase of 17 days among blacks compared to whites
*p=<0.01 and Adjusted for age at diagnosis, diagnosis year, hormone-receptor status,
stage, grade urban status and distance to providers.
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Table 4.2 Diagnosis-to-hormone treatment times stratified by BCN**, marital
status*, early/late surgery and insurance provider

White
Black
Black-White
% Increase
p-value

LSM (95% C.I.)
Married (Yes)
190.08
210.11
20.03
10.54
0.19

LSM (95% C.I.)
Married (No)
166.42
213.01
46.59
28.00
<0.01

White
Black
Black-White
% Increase
p-value

BCN (Yes)
173.63
175.85
2.22
1.28
0.93

BCN (No)
153.78
186.24
32.46
21.11
<0.01

White
Black
Black-White
% Increase
p-value

Surgery 30 (Early)
154.39
178.76
24.37
15.78
0.07

Surgery 30 (Late)
169.94
211.47
41.53
24.43
0.01

White
Black
Black-White
% Increase
p-value

Surgery 60 (Early)
165.53
187.91
22.38
13.52
0.06

Surgery 60 (Late)
158.91
221.75
62.84
39.54
0.01

Insurance provider 1
Insurance provider 2
White
160.23
188.27
Black
206.09
189.20
Black-White
45.87
0.93
% Increase
28.63
0.49
p-value
<0.01
0.96
*All models adjusted for age at diagnosis, diagnosis year, hormone-receptor status, stage,
grade urban status and distance to providers.
**Best Chance Network
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Table 4.3 Racial disparities among breast cancer patients and the odds of late
receipt of surgery stratified by marital status, urban status and distance
Charact
eristic

Late receipt
(>22 days)
1123(55.02
%)
No (%)
770(52.38)

Crude OR

Adjuste
d OR*

1470(72.02)

Early
receipt
(<22 days)
918(44.98%)
No (%)
700(47.62)

OR (CI)
Reference

Black

571(27.98)

218(38.18)

353(61.82)

Married
Yes White

1.47(1.211.79)

OR (CI)
Referenc
e
1.59(1.2
8-1.98)

965(80.89)

463(47.98)

502(52.02)

Reference

Black

228(19.11)

100(43.86)

128(56.14)

No White

409(57.93)

187(45.72)

222(54.28)

1.18(0.881.58)
Reference

Black

297(42.07)

96(32.32)

201(67.68)

Urban
status
Rural White

1.76(1.292.41)

308(62.47)

160(51.95)

148(48.05)

Reference

Black

185(37.53)

67(36.22)

118(63.78)

Urban White

1162(75.06)

540(46.47)

622(53.53)

1.90(1.312.77)
Reference

Black

386(24.94)

151(39.12)

235(60.88)

1.35(1.071.71)

Distanc
e
<=10mil White
es
Black

526(70.79)

283(53.80)

243(46.20)

Reference

Overall

Race

Total

White

Referenc
e
1.39(1.0
0-1.92)
Referenc
e
1.96(1.3
8-2.79)

Referenc
e
2.40(1.5
5-3.73)
Referenc
e
1.40(1.0
8-1.82)

Referenc
e
217(29.21)
87(40.09)
130(59.91)
1.74(1.26- 1.89(1.3
2.40)
2-2.71)
>10 White 831(72.89)
385(46.33)
446(53.67)
Reference Referenc
miles
e
Black 309(27.11)
120(38.83)
189(61.17)
1.36(1.04- 1.49(1.1
1.77)
1-2.01)
*Models adjusted for age, diagnosis year, hormone-receptor status, stage, grade and
being in best chance network (BCN), definitive surgery type and insurance provider.
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Table 4.4 Racial disparities among breast cancer patients and the odds of late
receipt of post-surgery radiation stratified by age, hormone receptor status, best
chance network, and insurance provider.
Chara
cteristi
c
Overal
l

Race

White
Black

Age
<45

White
Black

45-54

White
Black

55-64

White
Black

Horm
one
Recept
or
Status
Positiv
e
Negati
ve

Total

Early receipt
(<60 days)
675(48.67%)
No (%)

Late receipt
(>60 days)
712(51.33%)
No (%)

Crude
OR

Adjusted
OR*

OR (CI)

OR (CI)

995(71
.74)
392(28
.26

508(51.06)

487(48.94)

Reference

Reference

167(42.60)

225(57.40)

1.41(1.111.78)

1.17(0.86
-1.56)

171(66
.80)
85(33.
20)
412(69
.95)
177(30
.05)
412(76
.01)
130(23
.99)

82(47.95)

89(52.05)

Reference

Reference

25(29.41)

60(70.59)

192(46.60)

220(53.40)

2.21(1.27- 2.18(0.99
3.85)
-4.80)
Reference Reference

76(42.94)

101(57.06)

234(56.80)

178(43.20)

66(50.77)

64(49.23)

1.27(0.861.89)

0.93(0.56
-1.57)

Reference

1.16(0.81- 0.95(0.59
1.65)
-1.53)
Reference Reference

White

464(76
.32)

246(53.02)

218(46.98)

Reference

Black

144(23
.68)
110(60
.44)

57(39.58)

87(60.42)

32(29.09)

78(70.91)

1.72(1.18- 1.44(0.86
2.52)
-2.39)
Reference Reference

72(39.
56)

23(31.94)

49(68.06)

White
Black

Insura
nce
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0.87(0.461.66)

0.30(0.10
-0.93)

provid
er
1

White

830(77
441(53.13)
389(46.87)
Reference Reference
.28)
Black
244(22
106(43.44)
138(56.56)
1.48(1.10- 1.29(0.88
.72)
1.97)
-1.89)
2 White 165(52
67(52.34)
98(59.39)
Reference Reference
.72)
Black
148(47
61(41.22)
87(58.78)
0.98(0.62- 0.84(0.47
.28)
1.53)
-1.53)
* Models adjusted for marital status, urban status, diagnosis year, stage, grade, distance,
definitive surgery type and receipt of early/late surgery.

67

Table 4.5 Racial disparities among breast cancer patients and the odds of late
receipt of chemotherapy stratified by urban status and late surgery
Charac
teristic

Race

Total
1134(100
%)

Early receipt
(<60 days)
556(51.44%)
No (%)

Late receipt
(>60 days)
578(50.97%)
No (%)

797(70.28
)
337(29.72
)

410(51.44)

387(48.56)

146(43.32)

191(56.68)

164(59.42
)
112(40.58
)

94(57.32)

70(42.68)

39(34.82)

73(65.18)

633(73.78
)
225(26.22
)

316(49.92)

317(50.08)

107(47.56)

118(52.44)

329(73.60
)
118(26.40
)

2012(61.40)

127(38.60)

Overall
White
Black

Rural/
Urban
Rural

White
Black

Urban

White
Black

Surger
y
Early

White

Crude
OR

Adjuste
d OR*

OR
OR (CI)
(CI)
Referen Referenc
ce
e
1.39(1. 1.00(0.6
078-1.48)
1.79)

Referen Referenc
ce
e
2.51(1. 1.93(0.8
531-4.60)
4.13)
Referen Referenc
ce
e
1.10(0. 0.76(0.4
818-1.21)
1.49)

Referen Referenc
ce
e
Black
74(62.71)
44(37.29)
0.95(0. 0.84(0.4
613-1.62)
1.46)
Late White 433(67.87
195(45.03)
238(54.97)
Referen Referenc
)
ce
e
Black 205(32.13
68(33.17)
137(66.83)
1.65(1. 0.89(0.5
)
172-1.52)
2.34)
* Models adjusted for age, marital status, diagnosis year, stage, grade, distance, insurance
provider, and definitive surgery type.
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CHAPTER 5

ASSESSMENT OF RACIAL DISPARITIES IN MORTALITY AMONG
BLACKS AND WHITES DIAGNOSED WITH BREAST CANCER IN
SOUTH CAROLINA

Introduction
Statistics over the past 20 years in the United States have shown higher mortality
rates among Blacks with breast cancer (BrCA) compared to Whites despite lower
incidence of BrCA among Blacks.(1-4) The need to study disparities on survival among
BrCA patients in SC is particularly important because Black-White disparity in BrCA
mortality is of a higher magnitude in SC;(30, 40, 41) mortality among White BrCA patients
is 7% lower in SC compared to the national average and is 29% higher among Blacks in
SC.(30, 40, 41) Also, in SC, mortality from BrCA amongst Blacks is greater than 60% than
that of Whites.(5) Studies also show that Blacks experience worse mortality outcomes
after matching for known prognostic factors, and this finding has persisted over time.(4245)

Factors that have been shown to influence BrCA survival are age, enrolment in
best chance network, socioeconomic status, hormone receptor status, health insurance
type, stage at diagnosis, type of surgery, complications of surgery, marital status and
county of residence (whether rural or urban).(55, 65, 67, 71, 72, 74, 79, 105, 124, 128, 140, 142, 143, 145, 14869

151)

This study will add to existing body of literature on racial disparities BrCA-specific

survival (BSS),(56) and overall survival (OS).(57, 58) Assessment of survival differences in
this study by regions in SC has not been studied before. The aim of this study was to
describe the breast cancer-specific and overall survival in SC, as well as by the four
health regions and to assess the factors (confounders and effect modifiers) affecting
survival among Black and Whites in SC overall. We hypothesize that treatment and
mortality outcomes will be worse for Blacks who live in Pee Dee, which are
characterized by lower socioeconomic status, and will be better in Midlands and Low
Country because of the major hospital systems available in these regions.
Methods
Data Source
This was a retrospective cohort study (2002 to 2010) that included data on all
BrCA patients derived from linked files from the SCCCR and Office of Revenue and
Fiscal Affairs (which maintains the administrative medical claims data for a private payor
plan and Medicaid). The study was exempt from IRB review by the University of South
Carolina IRB. All newly diagnosed cases of cancers are collected by SCCCR, which is a
population-based system in SC. Data in the SCCCR include information on
demographics, diagnosis date, cancer location and histology, treatment and overall
survival.(38) All incident cancer cases are required by law to be reported to SCCCR, a
resource established with funding from an award from the National Program of Cancer
Registries (NPCR) in 1994.
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The SCCCR from which we derived the data for this analysis has a history of
receiving the highest/gold rating for data completeness (>94%), timeliness and data
quality from the North American Association of Central Cancer Registries and NPCR.
SCCCR is a member of the CDC National Interstate Data Exchange System (N-IDEAS),
such that any member state may share resident incident cases with others to ensure the
completeness of incident cancer data. A cohort of 2,155 patients from the SCCCR with a
diagnosis of female breast cancer from 2002 to 2010 was created. This cohort was linked
to the same patients in the SC State Employee Health Plan and Medicaid datasets. The
resulting combined dataset were used to conduct all analyses.
Data Linkage and Security
Linkages were made with 3 personal identifiers: name, date of birth and social
security number. These linkages were performed by RFA in partnership with SCCCR.
Because of data security issues, only the final de-identified dataset was released to study
personnel and investigators for analysis. The key to the de-identified dataset was retained
by RFA in the event that further data clarifications were needed from the primary record.
Once the de-identified data were received, the study data manager performed routine
outlier and logic checks. Any improbable values were verified with RFA or SCCCR and
rectified where possible. To create an analytic dataset, we utilized datasets from the RFA
(Medicaid and State Health Plan), BCN and SCCCR to create an extensive look at breast
cancer treatment in South Carolina for Black and White women. Data acquisitions were
linked through the aforementioned departments by the RFA, and only a study participant
number was assigned to each person for analysis by investigators. Because the final
dataset was completely de-identified, the investigators have no linkages to the original
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identifiable patient contact information and will be referred to via a study participant
number only.
Variables
Exposure Variable: The main exposure variable was race of the BrCA cases,
dichotomized as Black or White. Variables that were considered as covariates or effect
modifiers were age, marital status, county of residence, year of diagnosis, hormone
receptor status, enrollment in BCN (dichotomized as yes or no), stage of BrCA at
diagnosis and grade of BrCA at diagnosis.
Outcome Variables: Overall and breast cancer mortality. We utilized vital
status, total survival time, and BrCA cause of death (yes/no) for this investigation. From
cause of death information, we were able to examine both all-cause/overall mortality, as
well as BrCA-specific mortality.
Exploratory Data Analysis: Kaplan-Meier survival curves were used to explore
5-year and 12-year survival for BrCA-specific and all-cause survival at the state and
regional levels. This was also stratified by race at the state and regional levels. Log rank
test was used to assess the Kaplan-Meier plot with respect to race which was the main
exposure. To test for adequacy of proportional hazard (PH) model, we graphically
inspected whether the log-log survival (lls) curve were parallel with respect to the
exposure of interest (race). The PH model was satisfied as the curves were parallel. Each
exposure variable was tested utilizing the Schoenfeld Residual to ascertain the adequacy
of using PH model. The PH model was satisfied for all variables tested.
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Assessment of interactions: In assessing the relationship between race and
mortality, interactions were assessed. Statistically significant interactions were noted
between race and marital status; race and urbanicity; race and region; race and BCN. The
analyses that assessed factors that influence disparity in mortality were therefore
stratified by these four variables.
Fitting the best model in each stratum: In each stratum, the relationships
between race and mortality (breast-cancer specific and all-cause) were assessed by fitting
the best Cox PH model through backward elimination starting with all potential
covariates like age, year of diagnosis, hormone receptor status, enrollment in BCN
(dichotomized as yes or no), stage of BrCA at diagnosis and grade of BrCA at diagnosis.
Results
Descriptive statistics for this study sample are shown in Table 1. Overall, there
were 2155 cases of breast cancer patients of which the majority were Whites (1557,
72.25%). In bivariate analyses, there were significant differences between Blacks and
Whites in age, rural/urban status, year of diagnosis, hormone receptor status, cancer
grade, cancer stage and insurance provider. Blacks were more likely to be in age group
45-54 (45.99%) while Whites were more likely to be in age group 55-64 years (41.88%).
Blacks were more likely to be unmarried (57.17%) compared to Whites (29.95%). The
proportion of Whites that live in urban area (79.13% vs 67.22%) and have hormone
receptor positive cancer (81.03% vs 68.89%) is higher among Whites compared to
Blacks. More Blacks were participants in BCN compared to Whites (9.87% compared
with 3.85%).
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Figure 1 presents the Kaplan Meier plots of 12-year BrCA-specific mortality
among Blacks and Whites in the state of SC and in Low Country region. There was
statistically significant difference between Blacks and Whites in the state overall;
however, among the 4 health regions, only the Low Country region had statistically
significant difference with mortality higher among Blacks. This difference is seen as
early as 3 years and it continues to widen till 12 years. Figure 2 is the all-cause mortality
variant of Figure 1 and the findings are similar to that of Figure 1.
Table 2 shows the 5- and 12- year survival proportion for BrCA-specific and allcause mortality among Blacks and Whites in the entire state of SC and also by the 4
health regions in SC. Table 2 shows that both the 12- year BrCA specific survival
(91.3%) and the 12-year overall survival (89.3%) were highest in Low Country region,
however, the black-white disparity was also higher in this region. As seen in Figure 1 and
2, Table 1 also shows that there is significant increase in mortality among Blacks relative
to Whites in the data that examined the state of SC and in the Low Country region of the
state.
The crude hazard ratio of mortality among Blacks compared with Whites was
1.42 (1.03, 1.95) for overall survival and 1.49 (1.04, 2.14) for BrCA specific survival
(data not shown). Table 3 presents the Cox proportional hazard models. Multivariable
Cox proportional hazard that adjusted for cancer stage showed that the hazard ratio of
mortality was 3.45 (1.64,7.25) among Black women who lived in Low Country region of
the state compared with White women who lived in Low Country region of the state
when all-cause mortality was examined. A similar hazard ratio of mortality of 3.79 (1.68,
8.58) was seen among Black women who lived in Low Country region of the state
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compared with White who lived in same region when BrCA-specific mortality was
examined. In the other three regions of the state (Midlands, Pee Dee and Upstate); there
were no statistically significant differences in hazard ratio that compared Blacks with
Whites. Multivariable Cox proportional hazard that adjusted for cancer stage and grade
showed that the hazard ratio of mortality was 1.53 (1.04,2.26) among Black women who
lived in urban areas compared with White women who lived in urban areas for all-cause
mortality.
Discussion
The Kaplan Meier model found that there was a statistically significant difference
between Blacks and Whites in the state of SC overall, however, among the 4 health
regions, only the Low Country region had statistically significant difference with
mortality higher among Blacks. This difference is seen as early as 3 years and it
continues to widen till 12 years. Also, in the Kaplan Meier model, the Low Country
region had higher BrCA survival than the other three regions, but it also demonstrated the
widest racial disparity. In Cox Proportional multivariable model, we also showed that
hazard ratio of mortality was 3.45(1.64,7.25) among Black women who lived in Low
Country region of the state compared with White women who lived in Low Country
region of the state when all-cause mortality was examined; and 3.79 (1.68, 8.58) was seen
among Black women who lived in Low Country region of the state compared with White
who lived in same region when BrCA-specific mortality was examined. Multivariable
Cox proportional hazard that adjusted for cancer stage and grade showed that the hazard
ratio of mortality was 1.53(1.04,2.26) among Black women who lived in urban areas
compared with White women who lived in urban areas for all-cause mortality.
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The crude hazard ratio of mortality among Blacks compared with Whites was
1.42 (1.03, 1.95) for overall survival and 1.49 (1.04, 2.14) for BrCA specific survival
which represents 40% excess risk for overall survival and 50% excess risk for BrCA
specific survival. However, this finding was no longer significant on multivariable model
which makes our finding different from previous similar studies in SC that found that
there is a 60% higher risk of Black women dying from BrCA compared to White women.
These previous studies showed that although the Black-White disparity in BrCA
mortality is seen both at the national level and in SC specifically, the disparity is of a
higher magnitude in SC (5, 30, 40, 41, 156); mortality among White BrCA patients is 7%
lower in SC compared to the national average and is 29% higher among Blacks in SC
(30, 40, 41). One of the possible reasons for these differences is because some of the
studies that assessed the mortality differences in SC utilized age adjusted mortality while
we utilized the Cox Proportional hazard model with adjustments. For example, a previous
study that found that a paradoxical relationship of a lower incidence of breast cancer but
higher death rates among Blacks considered the age-adjusted rate. (156) Our study
therefore underscores the additional importance of going a step further after utilizing ageadjusted data to also modelling using statistical means to assess the relationship between
mortality and race among BrCA patients.
We found from the Kaplan Meier model that the 5-year, and 12-year survival was
higher among Whites in the state of SC overall but when this was stratified by region,
only the Low Country region demonstrated a wide disparity while there was no
significant difference between Blacks and Whites in the other three regions. This finding
was additionally supported by the multivariable adjusted hazard ratio for mortality which
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showed that Blacks in the Low Country region had mortality hazard ratio of 3.45 (1.64,
7.25) after adjusting for cancer stage, cancer grade and age. This shows that the racial
disparities seen in BrCA mortality seen in SC is being driven mainly by the disparity seen
in Low Country region of the state. What is interesting though, is that using the Kaplan
Meier model, the Low Country had the highest 12-year survival for both all-cause and
BrCA specific mortality (91.3% and 89.3% respectively). It therefore appears that overall
(when Blacks and Whites are combined), Low Country has the best mortality outcome
related to the other three regions but when Black-White disparity is considered, the Low
Country has the highest racial disparity.
This finding may be helpful to help inform policy direction in the SC’s state BCN
program which is an early detection program for breast and cervical cancer (41, 141).
Women that are eligible for this program are those that are aged 47-64 years, residents of
SC, underserved/underinsured or do not have insurance and are of low income (less than
200% of the Federal poverty level). This program provides free breast and cervical cancer
screening and started because SC has one of the highest rates of uninsured women the
United States (40, 41, 141). Recruitment into the BCN program is usually through active
search by federally qualified health centers, the South Atlantic Division, media outlets
and through outreaches carried out by the American Cancer Society. (41, 141). Our
finding may help the administrators of the BCN program to plan and focus efforts to
reduce racial disparities to certain regions of the state or implement special programs for
those regions.
Obesity rate may be one of the factors affecting the racial disparities in the Low
Country region of SC. In SC, it has been hypothesized that comorbid illnesses and
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obesity could be the driver of cancer racial disparity. (157) Obesity and comorbid
illnesses affect Blacks in SC at a rate that is above the national average. (157, 158) In
2018 report, SC has the 10th highest adult obesity rate in the US, this is up from being the
13th highest in 2016. Comparing these figures to that of 2000 and 1999 (21.1% and 12%
respectively), the weight gain problem appears to be persistently on the rise in SC. (157,
158) A previous study as shown that severe obesity and high waist-to-hip ratio among
Blacks have also been found to contribute to racial differences in stage at BrCA
diagnosis, as Blacks had a higher likelihood of severe obesity and being in the highest
tertile of waist-to-hip ratio (64). SC diabetes and hypertension rate are currently 5th
highest and 8th highest (13.4% and 38.1% respectively) in the US and physical activity
ranking 17%. When the obesity rate in SC is broken down by Black-White race, it is
42.1% (ranking 9th) in Blacks while it is 29.6% (ranking 25th) in Whites. Specifically in
Charleston, the largest city in the Low Country, the overweight or obese rate is 73.1%
among Blacks and 63.4% among Whites. (159) When the obesity rate by county was
ranked, 56% (five out of nine) of counties that had the highest obesity rate in SC (obesity
rate >40%) were in Low Country region [Allendale, Bamberg, Colleton, Hampton and
Orangeburg]. (158)
The regional sub-population of the Gullahs may also be one of the factors
affecting the racial disparities in the Low Country region of SC. The Gullahs are a unique
Black sub-population that live and reside in the farming and the fishing communities
along SC’s coastal areas. (157) The Gullah community are geographically isolated and
previous studies have shown that they experienced limited access to health care and are at
a higher risk of cardiometabolic risk factors for diabetes mellitus. (160, 161) The
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Gullah’s limited access to care (though for diabetes mellitus) may also have affected their
receipt of care for BrCA as shown by other reports that Blacks also have various barriers
to accessing care. Blacks have been shown to consistently receive lower-thanrecommended BrCA care when compared with their White counterparts (21, 25, 43, 61,
73, 78). This includes lower-than-recommended rates of radiation after surgical treatment
for BrCA (25, 43, 61, 78). Blacks have also been shown to be 30-40% more likely to
receive BrCA treatments that are not in line with guidelines across all BrCA subtypes
(79). Previous studies have also shown that there is a tendency among Blacks to not
receive preventative services such as early screening mammograms (77).
Socioeconomic status (SES) has been identified as one of the main drivers of
racial disparities in BrCA mortality, as women in low socioeconomic levels tend to
present with more advanced-stage BrCA, which usually has poorer prognosis (71, 80).
Specifically, in Charleston, the median income in 2015 for a white family in Charleston–
North Charleston was more than double for black families, $64,553 compared to $29,799.
That means more than 15,000 black families in Charleston and North Charleston were
living on the edge of the poverty guideline—$24,250. Charleston County has is of the
worst counties in the United States in helping poor children up the income ladder. It ranks
242nd out of 2,478 counties, better than only about 10% of counties nationwide. (159)
Generally, the five-year survival rate is worse among population subgroups with lower
SES, which are usually comprised of a large proportion of Blacks (71, 81). Whereas
about 12% of Whites live below the poverty level, this proportion is 26% among Blacks
(71, 82). Additionally, when median income by county was ranked, 33 % (five out of 15)
of counties that had the lowest median income in SC (median household income <
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35,558) were in Low Country region [Allendale, Bamberg, Colleton, Hampton and
Orangeburg]. (158) These five counties were the same counties with the higher obesity
rate. (158)
This study added to existing body of literature on racial disparities on BrCAspecific survival (BSS), (56) and overall survival (OS) (57, 58). To our knowledge, this is
the first cancer disparity study in SC that has conducted a regional analysis thereby
showing that the Low Country region appears to be the driver of the racial disparities
seen in BrCA patients in SC. One weakness of this study is that we did not assess the
Hispanic population because the BrCA patients had very low sub-population in SC.
Additionally, our study was limited in the number of other biological, patient-, physician, and healthcare-system-related factors that could have been assessed to further study our
observations especially in the Low Country region.
In conclusion, mortality was higher among Blacks who lived in the Low Country
region of the state and among Blacks who lived in urban areas. Although the Low
Country region had the highest 12-year survival among a combination of Whites and
Black population, relative to other three health regions, it demonstrated the highest
Black-White racial disparity relative to the other three regions. Despite the awareness and
funding dedicated to closing the racial gap in cancer therapy, it is discouraging to note
that racial disparities persist in BrCA mortality (60, 61). Navigation programs and other
available programs aimed at reducing racial disparities may benefit from these finding by
committing more resources that are culturally acceptable to the Low Country region of
SC. Considering that Low Country seemed to have the best mortality outcome (when
combined data is used) but the worse Black-White disparity, the Low Country region
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may benefit from specific community-oriented interventions similar to the community
COMPASS project (157) that has the potential to close this gap. To reduce racial
disparity gap in survival in SC, Black breast cancer patients that live in Low Country
region and those that live in urban areas may benefit from more intense navigation efforts
directed at early detection and linkage to receipt of breast cancer treatments. Future
studies are also required to identify the potential, biological, patient-, physician-, and
healthcare-system-related factors underlying our observations and optimize cancer care
among Blacks in SC particularly in the Low Country region. Additionally, the state of SC
will benefit from future studies to assess the regional disparities in other common cancers
to identify if this trend seen in the Low Country specific to BrCA or other cancers in
order to inform future implementation regional appropriate policies that may help to close
this gap.
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Table 5.1 Summary of patients’ characteristics by race
N (%)

N (%)

N (%)

Total

White

Black

(N=2155)

N=1557

N=598

(72.25)

(27.75)

51.20(7.20)

51.60(6.99)

50.17(7.63)

<0.01

386(17.91)

256(16.44)

130(21.74)

<0.01

924(42.88)

649(41.68)

275(45.99)

845(39.21)

652(41.88)

193(32.27)

751(34.85)

436(29.95)

315(57.17)

Married

1256(58.28)

1020(70.05)

236(42.83)

Urban

1634(75.82)

1232(79.13)

402(67.22)

Rural

521(24.18)

325(20.87)

196(32.78)

2002-2004

611(28.35)

452(29.03)

159(26.59)

2005-2007

693(32.16)

518(33.27)

175(29.26)

2008-2010

851(39.49)

587(37.70)

264(44.15)

Positive

926(42.97)

709(81.03)

217(68.89)

Negative

264(12.25)

166(18.97)

98(31.11)

In-situ

422(21.72)

299(19.34)

123(20.78)

Characteristic

Age

P

(mean+SD)
Age

Under 45

categories

years old
45-54
years old
55-64
years old

Marital status

Not

<0.01

married
Rural/Urban

<0.01

status
Year of

0.02

diagnosis

Hormone

<0.01

receptor
status (both
hormones)
Stage at
Diagnosis

82

0.68

Cancer grade

Best Chance

Local

1013(47.01)

741(47.93)

272(45.95)

Regional

657(30.49)

470(30.40)

187(31.59)

Distant

46(2.13)

36(2.33)

10(1.69)

I

392(18.19)

300(21.29)

92(16.76)

II

785(36.43)

608(43.15)

177(32.24)

III

749(34.76)

479(34.00)

270(49.18)

IV

32(1.48)

22(1.56)

10(1.82)

Yes

119(5.52)

60(3.85)

59(9.87)

No

2036(94.48)

1497(96.15)

539(90.13)

Network
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<0.01

<0.01

Figure 5.1: Kaplan Meier curves for the association between race and 12-year
Breast Cancer Specific Mortality in SC
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Figure 5.2 Kaplan Meier curves for the association between race and 12-year AllCause Mortality in SC
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Table 5.2: 5-year and 12-year survival by region and by race in South Carolina
BrCA-specific survival
5YST (%)

12YST

Overall survival
5YST (%)

(%)
South

12YST
(%)

Overall

95.6

89.3

94.8

85.8

Black

93.3

85.5

92.8

81.2

White

96.5

90.1

95.7

87.3

Carolina

p-value
Midlands

0.03

0.03

Overall

95.6

89.3

94.8

85.3

Black

95.0

90.0

94.3

86.6

White

95.8

89.0

94.9

84.9

region

p-value
Low

0.70

0.46

Overall

95.5

91.3

95.0

89.3

Black

90.3

81.9

89.7

78.8

White

98.0

95.6

97.7

94.3

Country
Region

p-value
Pee Dee

<0.01

Overall

95.2

82.9

93.7

78.5

Black

94.7

80.1

95.0

75.7

White

95.5

87.4

93.4

82.7

p-value
Upstate

<0.01

0.67

0.76

Overall

96.1

90.7

95.8

87.5

Black

92.1

92.1

92.1

84.1

White

96.7

90.7

96.1

88.1

p-value

0.43

86

0.28

Table 5.3: Table HR and 95% CI for the associations between predictors and allcause and BrCA specific mortality by race in SC state overall
Character
istic
Overall
Married
Yes
No
Urban

Yes
No

Region
Low
Country
Midlands
Pee Dee
Upstate
BCN

Yes
No

Insurance
1

Race

Death

Adjusted HR**
Overall survival

White
Black

No (%)
112(7.19)
57(9.53)

HR (CI)
1.00
1.28(0.92,1.77)a

Adjusted HR**
BrCA-specific
survival
HR (CI)
1.00
1.30(0.90,1.88)a

White
Black
White
Black

70(6.86)
11(4.66)
36(8.26)
41(13.02)

1.00
0.78(0.41,1.47)b
1.00
1.53(0.97,2.42a

1.00
0.71(0.35,1.46)a
1.00
1.78(1.06,3.01)e

White
Black
White
Black

80(6.49)
39(9.70)
32(9.85)
18(9.18)

1.00
1.53(1.04,2.26)a
1.00
0.91(0.51,1.62)c

1.00
1.53(0.98,2.41)a
1.00
0.81(0.42,1.55)c

White

11(3.77)

1.00

1.00

Black
White
Black
White
Black
White
Black

19(12.70)
44(9.02)
12(6.59)
24(9.23)
18(10.29)
33(6.38)
8(8.99)

3.45(1.64,7.25)c
1.00
0.68(0.35,1.31)a
1.00
0.99(0.53,1.86)d
1.00
1.43(0.66,3.10)c

3.79(1.68,8.58)
1.00
0.72(0.35,1.51)a
1.00
0.94(0.44,1.98)f
1.00
1.32(0.54,3.21)

White
Black
White
Black

2(3.33)
11(18.64)
110(7.35)
46(8.53)

1.00
1.43(0.66,3.10)e
1.00
1.22(0.86,1.72)a

1.00
1.32(0.54,3.21)e
1.00
1.14(0.77,1.70)a

White
65(5.07)
1.00
1.00
Black
21(5.87)
1.09(0.66,1.80)a
1.06(0.61,1.85)a
2*
White
47(17.09)
1.00
1.00
g
Black
36(15.00)
0.89(0.57,1.40)
0.83(0.49,1.39)a
a
Adjusted for stage and grade. bAdjusted for stage and age.
c
Adjusted for stage. dAdjusted for stage, grade and age.
e
Crude HR reported because no additional variable met entry into the model for
adjustment.
f
Adjusted for age and grade
g
Adjusted for age, stage and diagnosis year.
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CHAPTER 6

GEOSPATIAL ASSESSMENT OF RACIAL BREAST CANCER
DISPARITY IN MORTALITY-TO-INCIDENCE RATIO AND
SURVIVAL ANALYSES CORRELATION IN SOUTH CAROLINA.

Introduction
The epidemiologic use of the mortality-to-incidence ratio (MIR) in cancer
research is gaining significance and is increasingly used (5, 10-14, 38) as a unique way to
quantify cancer disparities based on race (5, 10). The MIR is an important indicator that
offers additional information beyond what is represented through the individual incidence
and mortality rate measures. (5) The MIR also serves as a population-based
approximation of fatality (1/survival) given incidence by stabilizing the incidence and
mortality differences across cancer sites and racial groups (5, 10). Recommendations
have been made for cancer surveillance programs to use MIRs to monitor disparities
across racial/ethnic groups and geographic regions (5, 10-14, 38) as a proxy for survival,
but there is paucity of studies that assessed the effectiveness of MIR as a proxy for
survival among BrCA patients, especially in South Carolina where there is marked
Black-White disparity. (38)
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Previous studies have utilized the MIR as a surveillance tool and shown that SC
exhibits more extreme racial differences in cancer incidence, mortality and MIR than
other states or the nation. (30-38) Additionally, examining the MIR helped to highlight
health regions where this disparity is highest. (38) A major drawback of the MIR,
however, is that there is no method to account for censoring and loss to follow up.
Additionally, the MIR most likely counts the mortality from previous years while using
incidence from the current year hence it is not a classic case fatality proportion. It is also
not possible to adjust for covariates such as treatment, comorbidities or individual
socioeconomic status in MIR analysis. Another weakness is that the relationship between
the numerator (mortality) and the denominator (incidence) may not be direct because
persons diagnosed with BrCa may not die of BrCa, and persons who die after the
diagnosis of BrCa will survive for varying lengths of time, which the MIR cannot
account for.
The limitations of the MIR described above make it difficult to compare results of
MIR studies directly with those of survival studies. Survival studies are more complex,
time-consuming and expensive and require more skills to carry out. Additionally, data
needed to conduct survival analyses is not publicly available and date of diagnosis and
death are protected data elements which most cancer registries will not release. Using
MIR is less time-consuming, less expensive and requires fewer skills to carry out. (5) The
potential utility of the MIR in cancer surveillance programs for monitoring disparities
across racial/ethnic groups and geographic regions is substantial, as shown by previous
studies. (5, 10, 12, 14, 38) It is therefore important to see how the MIR compares with
survival studies in identifying racial disparities and in ranking health regions for the
89

purpose of surveillance. To our knowledge, this is the first study that seeks to directly
compute MIR by health regions and compare this ranking with a ranking produced by
median survival time to further substantiate the usefulness of the MIR in resource-poor
settings and in quick decision making to identify areas that need urgent interventions.
This study added further to the usefulness of MIR that was found from a
sensitivity analysis described previously by Sunkara et al. (152) that examined the effect
of moving across different “denominator years” to vary with the alignment of the average
incidence-to-mortality time interval. The sensitivity analysis used all combinations of sex
and race for cancers involving all anatomic sites. It was shown that the lines describing
the MIR remained parallel, with the rates generally remaining stable over time across
eight different 5-year periods beginning in 1996. This analysis was performed using
incidence data from the SC Central Cancer Registry (SCCCR) (152).
The aim of this work is to assess the validity of MIR as a proxy for survival and
geospatially investigate racial disparity among BrCA patients. This was achieved by
comparing the MIR methodology with survival methodology in assessing racial BrCA
disparities across the four health regions in SC. We hypothesize that the MIR will be a
valid analyses compared with survival analyses by region.
Methods
Data for survival analyses
Data for survival analyses is from a retrospective cohort study (2002 to 2010) that
included data on all BrCA patients derived from linked files from the SCCCR and Office
of Revenue and Fiscal Affairs (which maintains the administrative medical claims data
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for the South Carolina Public Employee Benefits plan and Medicaid). The study was
exempt from IRB review by the University of South Carolina IRB because it was a
deidentified data. All newly diagnosed cases of cancers are collected by SCCCR, which
is a population-based system in SC. Data in the SCCCR include information on
demographics, diagnosis date, cancer location and histology, treatment and overall
survival. (38)
The data was linked with data from SC Revenue and Fiscal Affairs Office (RFA)
which is an independent agency that houses administrative claims data from both SC
State Employee Health Plan and SC Medicaid plan members. The RFA developed a
series of algorithms using various combinations of personal identifiers to create its own
unique identifier, enabling statistical staff to “link across” multiple providers and settings.
Hence, it allows for linkages while protecting the confidentiality of the client. The SC
Revenue and Fiscal Affairs Office and SC Central Cancer Registry frequently work
together to complete data linkage requests for researchers in SC. All BrCA cases between
the time period of 2002 to 2010 who met eligibility criteria (that could be ascertained
from their files) were given to RFA. Then RFA matched to determine which cases linked
and further met our eligibility criteria (that required claims data to ascertain). This
resulted in the 2155 cases. This resulting combined dataset was used to conduct all
analyses.
This cohort was linked to the same patients in the SC State Employee Health Plan
and Medicaid datasets. The resulting combined dataset will be used to conduct all
analyses. Linkages were made with 3 personal identifiers: name, date of birth and social
security number. As per protocol, these linkages were performed by RFA in partnership
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with SCCCR. Because of data security issues, only the final de-identified dataset was
released to study personnel and investigators for analysis. The key to the de-identified
dataset was retained by RFA in the event that further data clarifications are needed from
the primary record. Once the de-identified data were received, the study data manager
performed routine outlier and logic checks. Any improbable values were verified with
RFA or SCCCR and rectified where possible.
To create an analytic dataset, we utilized datasets from the RFA (Medicaid and
State Health Plan), BCN and SCCCR to create an extensive look at breast cancer
treatment in South Carolina for Black and White women. Data acquisitions were linked
through the aforementioned departments by the RFA, and only a study participant
number was assigned to each person for analysis by investigators. Because the final
dataset was completely de-identified, the investigators have no linkages to the original
identifiable patient contact information and will be referred to via a study participant
number only.
Data for the MIR
Data for the MIR were obtained from SC Central Cancer Registry (SCCCR)
online query system which is in the SC Department of Health and Environmental Control
(DHEC) Office of Public Health Statistics and Information Services. Aggregate data for
the age-adjusted mortality and incidence rates were obtained from the SC DHEC. Data on
breast cancer was used in computing the incidence and mortality rates for BrCA, All
incident BrCA cases are required by law to be reported to SCCCR, a resource established
with funding from an award from the National Program of Cancer Registries (NPCR) in
1994. Enabling legislation from the SC General Assembly was enacted in 1996. Data are
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collected by SCCCR on all cancers, both in-situ and invasive, from hospitals, pathology
laboratories, freestanding treatment centers and physician offices. The only exceptions
are in situ forms of cervical cancer and invasive forms of basal and squamous cell skin
cancers of non-genital sites.
The SCCCR from which we will derive the data for this analysis has a history of
receiving the highest/gold rating for data completeness (>94%), timeliness and data
quality from the North American Association of Central Cancer Registries and NPCR.
SCCCR is a member of the CDC National Interstate Data Exchange System (N-IDEAS),
such that any member state may share resident incident cases with others to ensure the
completeness of incident cancer data. Additionally, there is geocoding of all cancer cases
and cancer deaths in the state of SC.
Variables for survival analyses
For the Kaplan Meier analyses and Cox Proportional hazard analyses, the main
predictor variable was race of the BrCA cases, dichotomized as Black or White. We
utilized vital status, total survival time, and BrCA cause of death (yes/no) for this
investigation. From cause of death information, we were able to examine both allcause/overall mortality, as well as BrCA-specific mortality. For Cox Proportional
analyses (to compute hazard ratio by region), additional variables that were considered as
covariates or effect modifiers were age, marital status, county of residence, year of
diagnosis, hormone receptor status, enrollment in BCN (dichotomized as yes or no), stage
of BrCA at diagnosis and grade of BrCA at diagnosis.
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Variables for MIR
Comparisons of MIRs across the four DHEC health regions (Upstate, Midlands,
Low Country and Pee Dee) was carried out. The variables that were utilized to calculate
the MIR were age-adjusted incidence and age-adjusted mortality. Variables that were
used to stratify the MIR maps across the four health regions are race of the BrCa cases
dichotomized as Black or White.
Analyses
Survival Analyses
Kaplan -Meier survival curves were used to explore 5-year survival and 12-year
survival for BrCA-specific and all-cause survival at the state and regional levels. This
was also stratified by race at the state and regional levels. Log rank test was used to
assess the Kaplan-Meier plot with respect to the main exposure (race) within the four
regions in SC.
Computing MIR
This study described BrCA disparities in SC among Blacks and Whites using
MIRs by race for the four health regions and by 46 counties within SC. We proceeded to
rank the four health regions by race from the worst to the best using MIRs. MIR were
computed from Cancer incidence and mortality data which were obtained from the SC
Community Access Network. In order to compare racial differences in BrCa MIRs in the
four SC DHEC health regions, seven categories (for county maps) of BrCa MIRs were
defined. First, the MIR were computed for Whites nationally (93) (i.e., for the US from
the United States Cancer Statistics at the Centers for Disease Control and Prevention) as a
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reference. The upper limit for Category 1 was the reference; the upper limit of Category 2
was 10% higher than the reference; the upper limit of Category 3 was 20% higher than
the reference; the upper limit of category 4 was 30% higher than the reference; the upper
limit of category 5 was 40% higher than the reference; the upper limit of category 6 was
50% higher than the reference and Category 7 consisted of MIRs >50% higher than the
reference. This method of categorization and analysis was adapted from a previous study
by Hebert et al. and Babatunde et al. (5, 38)
Computing MIR for four health regions:
BrCa MIRs by race (Black vs. White) were computed for years 2002-2010. Years
2002 to 2010 will be utilized to mirror the years of registry data that were obtained for
the survival analyses. The age-adjusted incidence and mortality rates will first be
calculated using incidence and mortality data from SCCCR. MIRs were stratified by race,
specifically Blacks versus Whites.
Computing MIR for 46 counties:
BrCa MIRs by race (Black vs. White) were computed for years 1996-2016.
Additional years were utilized to compute Black-White differences in MIR. This was not
utilized for the MIR-Survival comparison because the years were outside the range for
the survival data. This was utilized to visually inspect the extent of the Black-White
disparities that exist when mapped in ArcGIS.
Interpreting the MIR
As a ratio with the mortality rate as the numerator and the incidence rate as the
denominator, the MIR takes on numeric values ranging from 0 to 1. Values closer to 0
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indicate more indolent cancers, whereas those closer to 1 indicate more aggressive
cancers. The MIR, which has been shown to be highly insensitive to time-discordant
incidence and mortality (152), does not take into account follow-up time and is not
equivalent to Cox proportional hazards–type survival analysis, which is a truly
multivariate technique that accounts for follow-up time. Similarly, the MIR cannot
account for competing risk.
Mapping to visually compare MIR and Survival using ArcGIS 10.2
ArcGIS 10.2 was utilized to map BrCA MIRs by race (46 counties and 4 regions).
MIR were categorized into seven levels (as described above) using the national MIR for
BrCA as reference in county map. In order to map BrCA MIRs by race across the four
health regions in SC, the categorizations were made based on the natural breaks created
by ArcGIS. In ArcGIS, MIRs were mapped using choropleth maps that utilized graduated
colors under quantities. The color ramp that were utilized for the maps was a color
spectrum that consisted of green (the best/lower MIR) to red (the worst/higher MIR).
Also, in ArcGIS, survival was symbolized using graduated symbols under quantities with
a blue circle 22. The biggest circle size symbolized worse/lowest survival while the
smallest circle size symbolized best/highest survival.
Correlation analyses to compare MIR and Survival using SAS 9.4
Survival-MIR correlation analyses were computed for all BrCA cases in each
county/region utilizing SAS software. SAS® Version 9.4 (Cary, NC) was utilized to
compute correlation analyses comparing MIR with 5- and 12-year survival. Correlation
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analysis was also computed comparing hazard ratio with MIR. Pearson’s correlation was
utilized, and statistically significant correlation was determined using a p-value of 0.05.
Results
A total of 2155 breast cancer patients (nWhites=1557/72%; nBlacks= 598/28%) were
reported in the study period. Table 1 shows the MIR by county by race. Graphically, in
Figure 1, the map showed that Blacks were in the higher MIR categories in almost all
counties while Whites were in the lower MIR categories in almost all the counties. Table
2 showed that the largest Black-White difference in all-cause 12-year and 5-year survival
percentage was seen in Low Country region (15.5% and 8.0% respectively). The largest
Black-White difference in BrCA specific 12-year and 5-year survival percentage was also
seen in Low Country region (13.7% and 7.7% respectively). Although the lowest MIR
overall was seen in the Low Country region when the entire population of Whites and
Blacks were considered, the highest difference in Black-White MIR was also seen in the
Low Country region.
The crude hazard ratio of mortality among Blacks compared with Whites was
1.42 (1.03, 1.95) for overall survival and 1.49 (1.04, 2.14) for BrCA specific survival (not
presented in table). Multivariable cox proportional hazard that adjusted for cancer stage
showed that the hazard ratio of mortality was 3.45 (1.64,7.25) among Black women who
lived in Low Country region of the state compared with White women who lived in Low
Country region of the state when all-cause mortality was examined. A similar hazard
ratio of mortality of 3.79 (1.68, 8.58) was seen among Black women who lived in Low
Country region of the state compared with White who lived in same region when BrCAspecific mortality was examined. In the other three regions of the state (Midlands, Pee
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Dee and Upstate); there were no statistically significant differences in hazard ratio that
compared Blacks with Whites.
Table 3 presented the Pearson Correlation coefficients that compared MIR with 5year survival, 12-year survival and adjusted hazard ratios for all-cause and BrCA-specific
survival for all patients and stratified by race. When MIR for all cases were considered,
there was statistically significant correlation between MIR for all cases and BrCA
specific 12-year survival (p: 0.01; r: -0.99); between MIR for all cases and all-cause 12year survival (p: <0.01; r: -0.99). The relationship showed that the higher the MIR, the
lower the survival. Similar pattern was shown with MIR for Whites and survival but there
was no statistically significant correlation between MIR for Blacks and their survival
percentage. There was also significant correlation between the difference in White-Black
BrCA specific 5-year survival and difference in Black-White MIR (p: 0.03; r: 0.97);
between the Black versus White adjusted multivariable all-cause hazard ratio and
difference in Black-White MIR (P: 0.05; r: 0.95).
Figure 2 graphically shows the relationship between survival and MIR for all
cases while Figure 3 graphically shows same relationship among Whites. Both maps
showed that there is a strong correlation between MIR and survival. The higher the
survival percentage (positive and desired), the lower the MIR (positive and desired).
Since this relationship was not seen among Blacks, this was not mapped. Figure 4
graphically shows the relationship between the Black-White difference in MIR and
White-Black difference in BrCA specific 5-year survival (p: 0.03; r: 0.97). This showed
that survival was highest where the MIR difference was lowest (Midlands region). Also,
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in Figure 4, all-cause hazard ratio for Blacks versus Whites was highest in the Low
Country region where the Black-White difference was highest.
The map showed that Blacks were in the higher MIR and lower survival
categories while Whites were in the lower MIR and higher survival categories. There
were multiple statistically significant correlations between MIR and survival overall;
MIR and survival among Whites; and Black-White difference in MIR versus BlackWhite difference in survival (all p-values were <0.05). Low Country region was
identified as the region with worse Black-White MIR and survival disparity.
Discussion
This study found that Blacks were in the higher/worse MIR categories in most of
the counties while Whites were in the lower/better MIR categories in most of the
counties. The largest Black-White difference was seen in Low Country region. While the
lowest/better MIR overall was seen in the Low Country region when the entire
population of Whites and Blacks were considered, the highest difference in Black-White
MIR was also seen in the Low Country region. When MIR for the entire population were
considered, there was statistically significant correlation between MIR and survival (p:
0.01; r: -0.99); between MIR for all cases and all-cause 12-year survival (p: <0.01; r: 0.99). The relationship showed that the higher the MIR, the lower the survival. Similar
pattern was shown with MIR for Whites and survival but there was no statistically
significant correlation between MIR for Blacks and their survival percentage.
Additionally, we found that there was also significant correlation between the difference
in White-Black BrCA specific 5-year survival and difference in Black-White MIR (p:
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0.03; r: 0.97); between the Black versus White adjusted multivariable all-cause hazard
ratio and difference in Black-White MIR (P: 0.05; r: 0.95).
Recommendations have been made for cancer surveillance programs to use MIRs
to monitor disparities across racial/ethnic groups and geographic regions (5, 10-14, 38) as
a proxy for survival and our study helped to assess the effectiveness of MIR as a proxy
for survival using cancer-specific survival among BrCA patients, especially in South
Carolina where there is marked Black-White disparity. (38) Our finding showed that MIR
mirrors BrCA survival across the health regions. Asadzadeh et al computed the validity
of the MIR as a proxy for site-specific cancer survival in 2010 in which relative survival
data was utilized. (162)
We have shown that despite the known drawbacks of MIR such as not accounting
for censoring and loss to follow up, counting the mortality from previous years while
using incidence from the current year, inability to account for covariates and competing
risks; the MIR is still a fair reflection of survival and racial disparities. The MIR may
therefore be utilized as a proxy for survival studies which are a more complex, timeconsuming and expensive analyses that require more skills to carry out. Using MIR is
less time-consuming, less expensive and requires fewer skills to carry out. (5) Therefore,
the potential utility of the MIR in cancer surveillance programs for monitoring disparities
across racial/ethnic groups and geographic regions is substantial, as shown by previous
studies. (5, 10, 12, 14, 38) and our current study.
Our study also found that the Black-White MIR difference is highest in the Low
Country region which is directly correlated with White-Black 5-year survival difference.
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This also agrees with the use of the MIR as a surveillance tool in past studies which
underscores the point that SC exhibits more extreme racial differences in cancer
incidence, mortality and MIR than other states or the nation. (30-37) Specifically, in a
previous study in SC, the MIR helped highlight regions where this disparity is highest
(38). For example, in this past study, the Pee Dee region in SC have the highest MIR
disparity, where the MIRs of Blacks are 3.1 and 3.0 times higher, respectively, than those
of Whites. Also, in our current study, the MIR for Blacks was highest in the Pee Dee
region (0.217) although the Black-White disparity was highest in the Low Country
region.
The Pee Dee region is known for its lower socioeconomic status, rurality and
being medically underserved (5). Additionally, in four of the 12 counties in the Pee Dee
regions (Dillon, Lee, Marlboro and Williamsburg), over 40% of adults report a BMI of
30 or more (153). Similarly, the percentage of adults aged 20 and over reporting no
leisure-time physical activity was greater than 30% in seven counties (Chesterfield,
Darlington, Dillon, Lee, Marion, Marlboro and Sumter) out the 12 counties in the Pee
Dee region (153). The usefulness of the MIR in racial disparity was also buttressed by the
study by Wagner et al. that described racial cancer disparities and their potential
geographical determinants by calculating, comparing and mapping MIRs throughout the
state of Georgia (GA, United States). This study found that Blacks in GA had more fatal
cancers than Whites for all cancer sites evaluated (10). Additionally, examining the MIR
helped to highlight health regions where this disparity is highest. (38)
Our study also showed the importance of the assessment of racial disparity in
MIR and survival at the regional level, a step beyond the state level. We found that the
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disparity is highest in the Low Country region. This finding that highlighted the region
with the highest disparity in SC may be useful to help inform policy direction in the SC’s
state BCN program which is an early detection program for breast and cervical cancer
(41, 141).
Obesity rate may be one of the factors affecting the racial disparities in the Low
Country region of SC. In SC, it has been hypothesized that comorbid illnesses and
obesity could be the driver of cancer racial disparity. (157) Obesity and comorbid
illnesses affect Blacks in SC at a rate that is above the national average. (157, 158) In
2018 report, SC has the 10th highest adult obesity rate in the US, this is up from being the
13th highest in 2016. Comparing these figures to that of 2000 and 1999 (21.1% and 12%
respectively), the weight gain problem appears to be persistently on the rise in SC. (157,
158) The regional sub-population of the Gullahs may also be one of the factors affecting
the racial disparities in the Low Country region of SC. The Gullahs are a unique Black
sub-population known as the that live and reside in the farming and the fishing
communities along SC’s coastal areas. (157)
The Gullah community are geographically isolated and previous studies has
shown that they experienced limited access to health care and that they are at a higher
risk of cardiometabolic risk factors for diabetes mellitus. (160, 161) Socioeconomic
status (SES) has been identified as one of the main drivers of racial disparities in BrCA
mortality, as women in low socioeconomic levels tend to present with more advancedstage BrCA, which usually has poorer prognosis (71, 80). Specifically, in Charleston, the
median income in 2015 for a white family in Charleston–North Charleston was more than
double for black families, $64,553 compared to $29,799.
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A previous report shows that predictors that are environmental in nature affect
health and disparity, (59) but the influence of geographical factors has not been well
explored among younger women. This is particularly important because young Black
women (less than 65 years old) present with relatively more fatal BrCA, leading to higher
mortality among this group. (30, 40) Most studies on the MIR have been on international
comparisons of the MIR based on cancer management outcomes, health care systems
ranking, national healthcare disparities, across several countries. (162-169) We have
added to the literature that MIR can also be applied locally for the purpose of surveillance
and assessment of racial disparities.
To our knowledge, this is the first study that seeks to directly compute MIR by
health regions and compare this ranking with a ranking produced by five-year and 12year survival time to further substantiate the usefulness of the MIR in resource-poor
settings and in quick decision making to identify areas that need urgent interventions. The
is also the first time that the MIR will be utilized to assess BrCa disparities in addition to
the direct sensitivity analyses comparing MIR with survival analyses both on the state
and regional level. Identifying predictors of racial differences in survival by regions is
also unique as findings has the potential to help guide more result-oriented navigation
efforts. Overall, the study population (SC) in this study is unique because of the high
proportion of SC residents that live in rural areas and the high racial disparity found in
SC in other studies. (38, 170) One weakness however, of this study is that we did not
assess the Hispanic population because the BrCA patients had very low representation in
SC. Another weakness is that the data that we utilized for survival analyses was limited to
BrCA patients below the age of 65 years while the data that we utilized for the MIR
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contained all BrCA patients (this was necessary to get an age-adjusted mortality and
incidence). Because we got the incidence and mortality data from the South Carolina
Community Assessment Network/Department of Health and Environmental Control
website, there was no way to remove the 65+ from the data and still get an age-adjusted
rate.
This study finds that the health region ranking utilizing the MIR was highly
correlated with survival time in the overall population and among White population. It
may therefore be preferable to use the cheaper, faster and less time-consuming MIR,
which also requires fewer skills, to identify geographic disparities and rank health regions
to identify areas that require urgent attention/interventions. Additionally, the MIR is
cheap and easy to compute from existing relatively complete data. The MIR can be used
as a surrogate measure for a more expensive and time-consuming survival studies (38).
Additional studies with larger sample size may help to understand the relationship
between MIR and survival among Black population. Cancer surveillance programs may
use the MIR to monitor disparities across racial/ethnic groups and geographic regions
going forward. MIRs have the potential to serve as an indicator of the long-term success
of cancer surveillance programs.
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Table 6.1: MIR by race by county in SC (1996-2016)
County

MIR
Blacks

MIR
Whites

County

MIR Blacks

MIR Whites

Abbeville

0.19

0.12

Greenwood

0.20

0.16

Aiken

0.23

0.16

Hampton

0.25

0.17

Allendale

0.29

0.19

Horry

0.26

0.15

Anderson

0.17

0.14

Jasper

0.28

0.16

Bamberg

0.24

0.16

Kershaw

0.19

0.15

Barnwell

0.26

0.14

Lancaster

0.24

0.13

Beaufort

0.20

0.12

Laurens

0.21

0.15

Berkeley

0.15

0.13

Lee

0.30

0.16

Calhoun

0.18

0.19

Lexington

0.19

0.14

Charleston

0.20

0.11

McCormick

Cherokee

0.26

0.18

Marion

0.24

0.23

Chester

0.27

0.18

Marlboro

0.24

0.15

Chesterfield

0.19

0.18

Newberry

0.21

0.14

Clarendon

0.19

0.18

Oconee

0.26

0.15

Colleton

0.18

0.15

Orangeburg

0.24

0.14

Darlington

0.26

0.17

Pickens

0.22

0.12

Dillon

0.24

0.19

Richland

0.20

0.13

Dorchester

0.20

0.12

Saluda

0.29

0.19

Edgefield

0.26

0.16

Spartanburg

0.23

0.15

Fairfield

0.20

0.15

Sumter

0.19

0.16

Florence

0.26

0.15

Union

0.23

0.18

Georgetown

0.20

0.14

Williamsbur
g

0.27

0.18

Greenville

0.20

0.13

York

0.21

0.15
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Figure 6.1: Racial disparities in mortality-to-incidence ration of Breast Cancer for
Blacks and Whites in South Carolina
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Table 6.2 Breast Cancer: aSurvival Proportion and Mortality to Incidence Ratio
(MIR) (2002-2010) in South Carolina by Race and Health Region
All
Health
Region
b

e

LC
MD
PD
UP

Health
Region
b

LC
MD
PD
UP

White

Blacks

All
Cause
12YS
(%)
89.3
85.3
78.5
87.5

All
Cause
12YS
(%)
94.3
84.9
82.7
88.1

All
Cause
12YS
(%)
78.8
90.0
75.7
84.1

All

White

Blacks

BrCA
Sp
12YS
(%)
91.3
89.3
82.9
90.7

BrCA Sp BrCA
12YS
Sp
(%)
12YS
(%)
95.6
81.9
89.0
90.0
87.4
80.1
90.7
92.1

All

White

Blacks

White
-Black
All
Cause
12YS
(%)
15.5
-5.1
7.0
4.0
White
-Black
BrCA
Sp
12YS
(%)
13.7
-1.0
7.3
-1.4
White
-Black

All

White

All
Caus
e 5YS
(%)
95.0
94.8
93.7
95.8

All
Cause
5YS
(%)
97.7
94.9
93.4
96.1

All

White

BrC
A Sp
5YS
(%)
95.5
95.6
95.2
96.1
HR
AC

Black

WhiteBlack
All
All
Caus Cause
e 5YS 5YS
(%)
(%)
89.7
8.0
94.3
0.6
95.0
-1.6
92.1
4.0

Black WhiteBlack
BrCA
BrC
BrCA
Sp 5YS A Sp Sp 5YS
(%)
5YS
(%)
(%)
98.0
90.3
7.7
95.8
95
0.8
95.5
94.7
0.8
96.1
92.1
4
HR
BrC
A
Black

Health
MIR
MIR
MIR
MIR
Black White
White
Region
g
LC
0.155
0.133
0.207
0.074 c3.45
1.00
3.79
1.00
d
a
MD
0.163
0.145
0.208
0.063
0.68
1.00
0.72
1.00
e
f
PD
0.177
0.151
0.217
0.066
0.99
1.00
0.94
1.00
g
UP
0.159
0.145
0.214
0.069 c1.43
1.00
1.32
1.00
a
5YS: 5-year survival; 12YS: 12-year survival; BrCA: Breast Cancer.
b
LC: LowCountry region; MD: Midland region; PD: PeeDee region; UP: Upstate region.
c
Adjusted for stage
d
Adjusted for stage and grade.
e
Adjusted for stage, grade and age
f
Adjusted for age and grade
g
Crude HR reported because no additional variable met entry into the model for
adjustment
b
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Table 6.3: Correlation between aSurvival Proportion and Mortality to Incidence
Ratio (MIR) (2002-2010) in South Carolina among Breast Cancer Patients by race
and region.
Survival Variable
Survival by MIR for all patients
b
BrCA Specific 12 YS (All patients)
All Cause 12 YS (All patients)
BrCA Specific 5YS (All patients)
All Cause 5YS (All patients)

MIR Variable

MIR (All
patients)
MIR (All
patients)
MIR (All
patients)
MIR (All
patients)

p-value

Pearson
Correlation
Coefficient

0.01

-0.99

<0.01

-0.99

0.37

-0.63

0.15

-0.85

Black survival by Black MIR
Black BrCA Specific 12 YS
Black All Cause 12 YS
Black BrCA Specific 5 YS
Black All Cause 5 YS

Black MIR
Black MIR
Black MIR
Black MIR

0.85
0.52
0.62
0.45

0.15
-0.48
0.38
0.55

White survival by White MIR
White BrCA Specific 12 YS
White All Cause 12 YS
White BrCA Specific 5 YS
White All Cause 5 YS

White MIR
White MIR
White MIR
White MIR

0.02
0.03
0.02
0.06

-0.976
-0.97
-0.97
-0.94

Survival disparity by MIR
disparity
White-Black BrCA Specific 12 YS
White-Black All Cause 12 YS
White-Black BrCA Specific 5YS
White-Black All Cause 5 YS

Black-White MIR
Black-White MIR
Black-White MIR
Black-White MIR

0.30
0.09
0.03
0.11

0.70
0.91
0.97
0.88

0.05

0.95

0.07

0.93

Hazard Ratio by MIR disparity
All Cause Hazard Ratio Black versus Black-White MIR
White
BrCA Specific Hazard Ratio Black
Black-White MIR
versus White
a
5YS: 5-year survival; 12YS: 12-year survival;
b
BrCA: Breast Cancer
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Figure 6.2: Mortality-to-incidence ration of Breast Cancer for South Carolina
compared with 12-year survival
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Figure 6.3: Mortality-to-incidence ratio of White Breast Cancer patients in South
Carolina compared with White 12-year survival
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Figure 6.4: Racial disparity in Mortality-to-incidence of Breast Cancer in South
Carolina compared with 5-year survival and all-cause Hazard Ratio
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CHAPTER 7

OVERALL SUMMARY
Objectives
The aims of this study were:
1. To assess racial disparities in BrCA treatment time in South Carolina (SC) by
comparing diagnosis-to-treatment times for the various forms of treatment in
Blacks and Whites with BrCA and to assess related effect modifiers. We
hypothesize that the diagnosis-to-treatment wait time is higher among Blacks
compared to Whites for all BrCA treatment types in SC.
2. To analyze the breast cancer-specific and overall survival in SC, as well as by
four health regions and to assess the factors (confounders and effect modifiers)
affecting survival among Black and Whites in SC overall. We hypothesize that
treatment and mortality outcomes will be worse for Blacks who live in Pee Dee,
which are characterized by lower socioeconomic status, and will be better in
Midlands and Low Country because of the major hospital systems available in
these regions.
3. To assess the effectiveness of MIR as a proxy for survival and geospatially
investigate racial disparity among BrCA patients. This was achieved by
comparing the MIR methodology with survival methodology in assessing racial
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4. BrCA disparities across the four health regions in SC. We hypothesize that the
findings from MIR by regions will be similar to the survival analyses by regions.
Main Findings
This study demonstrated that there was a longer diagnosis-to-treatment time for
all treatment modalities for Blacks when compared with Whites. Late receipt of AHT was
higher among blacks that were unmarried, received late surgery, and not a participant of
the BCN. We also found that late receipt of surgery was higher among blacks that were
unmarried, lived in urban areas and those who lived less than 10 miles to their health care
provider. The only sub-group where whites had a later receipt of treatment was for postsurgery radiation among hormone receptor negative BrCA patients.
In addition to showing that there were longer diagnosis-to-treatment time in
which has been demonstrated from previous studies, (18, 22, 26, 74, 128) we were able to
add the following to the racial disparity discussion: the impact of being unmarried, living
in urban areas, enrolment in BCN, and distance on late receipt of treatment. This study
also showed the positive relationship between late receipt of surgery and time to AHT
demonstrating that those who are late to receive one form of treatment are likely to be
late at the receipt at other forms of treatment. The use of the findings in this paper has the
potential to further enhance the understanding of navigation of health care process and
strengthen navigation efforts aimed at linking women with BrCA to care especially
among blacks thereby reducing racial disparities.
The Kaplan Meier model found that there was a statistically significant difference
between Blacks and Whites in the state of SC overall, however, among the 4 health
regions, only the Low Country region had statistically significant difference with
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mortality higher among Blacks. This difference is seen as early as 3 years and it
continues to widen till 12 years. Also, in the Kaplan Meier model, the Low Country
region had higher BrCA survival than the other three regions, but it also demonstrated the
widest racial disparity. In Cox Proportional multivariable model, we also showed that
hazard ratio of mortality was 3.45(1.64,7.25) among Black women who lived in Low
Country region of the state compared with White women who lived in Low Country
region of the state when all-cause mortality was examined; and 3.79 (1.68, 8.58) was seen
among Black women who lived in Low Country region of the state compared with White
who lived in same region when BrCA-specific mortality was examined. Multivariable
Cox proportional hazard that adjusted for cancer stage and grade showed that the hazard
ratio of mortality was 1.53(1.04,2.26) among Black women who lived in urban areas
compared with White women who lived in urban areas for all-cause mortality.
We also found that Blacks were in the higher/worse MIR categories in most of the
counties while Whites were in the lower/better MIR categories in most of the counties.
The largest Black-White difference was seen in Low Country region. While the
lowest/better MIR overall was seen in the Low Country region when the entire
population of Whites and Blacks were considered, the highest difference in Black-White
MIR was also seen in the Low Country region. When MIR for the entire population were
considered, there was statistically significant correlation between MIR and survival (p:
0.01; r: -0.99); between MIR for all cases and all-cause 12-year survival (p: <0.01; r: 0.99). The relationship showed that the higher the MIR, the lower the survival. Similar
pattern was shown with MIR for Whites and survival but there was no statistically
significant correlation between MIR for Blacks and their survival percentage.
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Additionally, we found that there was also significant correlation between the difference
in White-Black BrCA specific 5-year survival and difference in Black-White MIR (p:
0.03; r: 0.97); between the Black versus White adjusted multivariable all-cause hazard
ratio and difference in Black-White MIR (P: 0.05; r: 0.95).
Conclusions
In conclusion, late receipt of AHT was higher among blacks that were unmarried,
received late surgery, and not a participant in BCN. We also found that late receipt of
surgery was higher among blacks that were unmarried, lived in urban areas and those
who lived less than 10 miles to their health care provider. There is a longer diagnosis-totreatment time in receipt of AHT between blacks and white that are not on BCN but no
difference between blacks and white on BCN, it therefore suggests that, perhaps the BCN
is helping to close the racial disparity gap between whites and blacks or those who are on
BCN have other factors that is driving the racial disparities.
We also noted found that mortality was higher among Blacks who lived in the
Low Country region of the state and among Blacks who lived in urban areas. Although
the Low Country region had the highest 12-year survival among a combination of Whites
and Black population, relative to other three health regions, it demonstrated the highest
Black-White racial disparity relative to the other three regions. Despite the awareness and
funding dedicated to closing the racial gap in cancer therapy, it is discouraging to note
that racial disparities persist in BrCA mortality (60, 61). Navigation programs and other
available programs aimed at reducing racial disparities may benefit from these finding by
committing more resources that are culturally acceptable to the Low Country region of
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SC. Considering that Low Country seemed to have the best mortality outcome (when
combined data is used) but the worse Black-White disparity, the Low Country region
may benefit from specific community-oriented interventions similar to the community
COMPASS project (157) that has the potential to close this gap.
Our study also showed that the health region ranking utilizing the MIR was highly
correlated with survival time in the overall population and among White population. It
may therefore be preferable to use the cheaper, faster and less time-consuming MIR,
which also requires fewer skills, to identify racial disparities and rank health regions to
identify areas that require urgent attention/interventions. Additionally, the MIR is cheap
and easy to compute from existing relatively complete data. The MIR can be used as a
surrogate measure for a more expensive and time-consuming survival studies (38).
Recommendations
The relationship between being on BCN and diagnosis-to-treatment time in
receipt on AHT will benefit from future studies as it will be important to understand the
reason for the longer time among those not on BCN. To improve overall timely receipt of
AHT, efforts need to be directed at Black BrCA patients that are not married, not on BCN
and received late surgery. To improve overall timely receipt of surgery, efforts need to be
directed at Black BrCA patients that are not married, lived in urban areas and lived <=10
miles from health providers.
To reduce racial disparity gap in survival in SC, Black breast cancer patients that
live in Low Country region and those that live in urban areas may benefit from more
intense navigation efforts directed at early detection and linkage to receipt of breast
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cancer treatments. Future studies are also required to identify the potential, biological,
patient-, physician-, and healthcare-system-related factors underlying our observations
and optimize cancer care among Blacks in SC particularly in the Low Country region.
Additionally, the state of SC will benefit from future studies to assess the regional
disparities in other common cancers to identify if this trend seen in the Low Country
specific to BrCA or other cancers in order to inform future implementation regional
appropriate policies that may help to close this gap.
Additional studies with larger sample size may help to understand the relationship
between MIR and survival among Black population. Cancer surveillance programs may
use the MIR to monitor disparities across racial/ethnic groups and geographic regions
going forward. MIRs have the potential to serve as an indicator of the long-term success
of cancer surveillance programs.
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